Podcasts about semaglutide

Semaglutide, Tirzepatide, and Retatrutide are often grouped together as GLP-1 medications, but they are not simply three versions of the same drug. In this episode, I compare the biology, research, and real-world implications behind each compound, looking beyond the number on the scale to ask a more useful question: what type of weight is being lost?I break down the progression from single agonist to dual agonist to triple agonist, including how GLP-1, GIP, and glucagon signaling may influence appetite, glucose regulation, energy expenditure, and fat loss. I also examine what the available body composition research shows about lean mass, visceral fat, skeletal muscle, and the risk of becoming lighter without becoming healthier or stronger.Topics discussed: - What actually separates the major GLP-1 medications- The scale - The body composition - Current evidence about retatrutide- Muscle prevention - Framework for evaluating weight loss outcomes---------- ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠My Live Program for Coaches: The Functional Nutrition and Metabolism Specialization ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.metabolismschool.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠---------- [Free] Metabolism School 101: The Video Series⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.metabolismschool.com/metabolism-101⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠----------Subscribe to My Youtube Channel: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://youtube.com/@sammillerscience?si=s1jcR6Im4GDHbw_1⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠----------⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Grab a Copy of My New Book - Metabolism Made Simple⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠---------- Stay Connected: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram: @sammillerscience⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube: SamMillerScience⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook: The Nutrition Coaching Collaborative Community⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TikTok: @sammillerscience⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠----------“This Podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast and the show notes or the reliance on the information provided is to be done at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for educational purposes only. Always consult your physician before beginning any exercise program and users should not disregard, or delay in obtaining, medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions. By accessing this Podcast, the listener acknowledges that the entire contents and design of this Podcast, are the property of Oracle Athletic Science LLC, or used by Oracle Athletic Science LLC with permission, and are protected under U.S. and international copyright and trademark laws. Except as otherwise provided herein, users of this Podcast may save and use information contained in the Podcast only for personal or other non-commercial, educational purposes. No other use, including, without limitation, reproduction, retransmission or editing, of this Podcast may be made without the prior written permission of Oracle Athletic Science LLC, which may be requested by contacting the Oracle Athletic Science LLC by email at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠operations⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@sammillerscience.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. By accessing this Podcast, the listener acknowledges that Oracle Athletic Science LLC makes no warranty, guarantee, or representation as to the accuracy or sufficiency of the information featured in this Podcast."

On this episode of Diabetes Connections In the news… The ADA conference controversy continues with a boycott now, new patch pump approved, an update on long running research to reverse type 1, plus consensus guidelines on T1D screening, intermittent fasting for type 1, a new surprising study about COVID and T1D, statins, type 2 and dementia, and lots more..  This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.  Want to let you know about a webinar I'm doing with Abbott later this month. That's Sept 23 at 7pm ET. We'll be talking about ketones, DKA and learn more about their dual CGM/ketone monitor that was just approved. Join us for a webinar September 23 Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Transcript: On this episode of Diabetes Connections In the news… The ADA conference controversy continues with a boycott now, an update on long running research to reverse type 1, plus consensus guidelines on T1D screening, intermittent fasting for type 1, a new surprising study about COVID and T1D, statins, type 2 and dementia, and lots more.. It's all coming up right after this. (AD BREAK) Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. We are off to Detroit this week for Moms' Night Out in Bloomfield Michigan. Super excited and as usual I'm getting last minute emails and DMs about respiration from people just finding out about the event. We will always figure it out so drop me a line. But please register now for Seattle next month! Tampa will be open soon as well! Want to let you know about a webinar I'm doing with Abbott later this month. That's Sept 23 at 7pm ET. We'll be talking about ketones, DKA and learn more about their dual CGM/ketone monitor that was just approved. Great crowd already registered for that, hope you can join us. The link is in the show notes. Okay.. our top story this week: XX Member of the American Diabetes Association… are now boycotting it. The notice of the boycott condemns leadership's actions after five researchers were removed by police from its annual meeting in June. Significantly, The editors of ADA's flagship journal, Diabetes Care, have joined on in support of the boycott. "Manuscripts submitted will not be handled until the boycott is over," said Steven Kahn, MBChB, the journal's editor in chief and one of the five researchers ejected from the meeting in New Orleans, in a LinkedIn post on Thursday. Kahn told MedPage Today that "the journal boycott is like establishing a picket line. The boycott already has hundreds of signatures of people who have pledged to suspend all ADA-related activities, including: Planning or attending any meetings led by ADA leadership or the board, including the 2027 ADA Scientific Sessions Participating in board-led activities regarding the investigation of the meeting's events, or the report generated by the "so-called 'independent' committee" Engaging in all other ADA operations, including presentations, fundraisers, grant reviews, manuscript reviews, journal management, manuscript submissions, and position statements The boycott will remain active until the ADA board of directors permits an independent formal review of the organization's structure and function to ensure it "properly represent[s] its professional membership." If demands are not met, signees plan to align with existing or newly formed medical societies. https://www.medpagetoday.com/endocrinology/diabetes/122977 https://docs.google.com/forms/d/e/1FAIpQLSd4h548X9qXgkVREQ71k2gDHiU8WFAFF78wTnmS20_ntwUM0w/viewform XX A new patch pump is coming to the US.. Beta Bionics, Inc. announces FDA clearance of Mint, the Company's patch pump featuring a transformative reusable and disposable architecture that does not require recharging, integrates with industry-leading continuous glucose monitors (CGM) and enables smartphone control for iOS and Android users. The Company expects to initiate the full commercial launch of Mint in the United States in the first quarter of 2027 Mint is expected to launch exclusively through the pharmacy channel. Also announced, that Eversense 365 is now compatible with Beta Bionics Senseonics expects development of the Eversense 365-iLet integration to be completed during the fourth quarter of 2026. Commercial launch is planned following completion of integration activities in the fourth quarter of 2026, subject to required testing, validation activities and applicable regulatory requirements. No word yet on timing for Eversense with Mint. https://www.manilatimes.net/2026/09/14/tmt-newswire/globenewswire/beta-bionics-announces-fda-clearance-of-mint-the-companys-transformative-patch-pump-and-unveils-3d-intelligence-as-its-next-generation-insulin-dosing-algorithm/2424457 XX Seven years after Johns Hopkins researchers discovered a previously unknown immune cell called the "X cell," they're now exploring whether that discovery could lead to a new treatment for type 1 diabetes. In preclinical studies, researchers developed an antibody that was able to target and eliminate specific immune cells responsible for attacking the pancreas's insulin-producing beta cells, while leaving the rest of the immune system intact. The researchers say the approach is especially promising because it could potentially reverse the autoimmune process soon after a type 1 diabetes diagnosis, rather than simply managing blood sugar. The work is still in the early stages and has not yet been tested in people; additional laboratory and preclinical studies are needed before human clinical trials can begin. sclerosis.https://hub.jhu.edu/2026/09/09/federal-funds-support-type-1-diabetes-treatment/ XX A new international consensus recommends routine screening for type 1 diabetes in the general population, offering the first framework for how healthcare providers could put widespread screening into practice. The guidance recommends screening children between ages 2 and 4, with children who test negative screened again at ages 6–8 and 10–15. Screening uses a blood test to look for islet autoantibodies, which can signal that the immune system is attacking insulin-producing cells years before symptoms appear or insulin is needed. Finding type 1 diabetes early can greatly reduce the risk of diabetic ketoacidosis, or DKA, at diagnosis and may give people access to treatments such as teplizumab that can delay progression to clinical T1D. https://www.prnewswire.com/news-releases/breakthrough-t1d-convened-paper-outlines-first-international-consensus-guidance-on-general-population-screening-for-early-stage-type-1-diabetes-302875788.html   XX Eating only between noon and 8 p.m. improved blood sugar control in a small study of adults with Type 1 diabetes and obesity, while avoiding an increase in serious complications. The promising findings offer the first evidence that time restricted eating could become another tool for managing the condition. For the study, Varady recruited adults with Type 1 diabetes who were also classified as obese After six months, the time-restricted eating group showed better blood sugar results than the calorie-reduction group. HbA1c, a blood test that reflects average blood sugar over the previous several months, fell by about 0.5% on average in the time-restricted group.   Couple of things here – very small study, only 32 people in total, who were then randomly placed in three groups with different styles of eating. Also, the lead researcher says this is the first study of it's kind for type 1 – which is obviously not true – you can do a quick google search or listen to past episodes of this show.. https://www.sciencedaily.com/releases/2026/09/260909231740.htm XX A large Danish study found that COVID-19 infection was associated with a slightly lower, rather than higher, risk of subsequently developing type 1 diabetes in people under age 30. Researchers studied more than 2,100 people diagnosed with T1D and found an overall 16% lower risk following a documented COVID infection, with the strongest association—a 42% reduction—seen 31 to 180 days after infection. The reduced risk appeared primarily among people who had not been vaccinated against COVID-19, although researchers cautioned that the vaccination findings were less certain. Importantly, this was an observational study, so it cannot show that COVID infection actually protects against type 1 diabetes or explain what caused the association. Researchers say the findings conflict with some earlier studies and should be investigated in other countries and populations. https://www.news-medical.net/news/20260908/COVID-19-linked-to-lower-subsequent-risk-of-type-1-diabetes.aspx   XX   Semaglutide, a medication widely used for type 2 diabetes and weight loss, may also provide an unexpected benefit for people with asthma. New research presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain, found that semaglutide use was associated with a reduction in asthma attacks of nearly 40%.   The study was led by Professor Chloe Bloom, Clinical Associate Professor in Respiratory Epidemiology at the National Heart & Lung Institute, Imperial College London, UK, and presented by Dr. Bohee Lee.       Exploring GLP 1 Drugs and Lung Health   Dr. Bloom said: "GLP-1 receptor agonists are widely used to treat type 2 diabetes and obesity. Previous research suggests that they may have anti-inflammatory effects and may improve lung-related outcomes. However, asthma and COPD outcomes have not been included as outcomes in GLP-1 drug trials.   "We wanted to use real-world health records to investigate whether people with asthma or COPD who started GLP-1 receptor agonists had fewer acute respiratory attacks."   To investigate that question, the researchers analyzed electronic medical records from the UK. They carried out four parallel studies, each involving between 20,000 and 22,000 people who had started treatment with either a GLP-1 medication or a different type of diabetes drug known as a sulfonylurea.   The results suggested that people with airway diseases such as asthma and COPD who received GLP-1 therapies experienced fewer asthma attacks and COPD flare-ups than comparable patients who were prescribed other diabetes medications.   Semaglutide Showed the Strongest Effect   Among the GLP-1 drugs examined, semaglutide appeared to stand out, particularly for people with asthma.   Bloom explains: "The effect was strongest with semaglutide, especially in people with asthma, where use of semaglutide appears to be associated with nearly a 40% reduction in asthma attacks. Semaglutide also led to a 20% reduction in COPD flare-ups."   The findings suggest that people who already qualify for GLP-1 receptor agonists because they have obesity or type 2 diabetes could potentially receive an additional benefit for their respiratory health.   However, Bloom emphasized that the results are not enough to recommend these medications specifically as treatments for asthma or COPD.   She explains: "The findings from this study are encouraging, but they should not change treatment decisions on their own. People with asthma or COPD should not start GLP-1 receptor agonists specifically for their lung condition outside current prescribing guidance. While the findings suggest that some people taking GLP-1 receptor agonists may experience fewer respiratory attacks, this needs confirmation in clinical trials." https://www.sciencedaily.com/releases/2026/09/260909005155.htm XX XX A large study suggests women with endometriosis may have a higher risk of developing type 2 diabetes. Researchers analyzed health records from nearly 3 million women in Utah and found those diagnosed with endometriosis were 46% more likely to develop type 2 diabetes than those without the condition. The association was strongest among women who had not yet reached menopause and those without obesity, a group typically considered at lower risk for type 2 diabetes. Certain forms of endometriosis, including those found outside the pelvic area, were associated with more than twice the risk. Researchers say more study is needed, but the findings suggest endometriosis may have health effects beyond the reproductive system and could eventually help identify women who may benefit from earlier diabetes screening. https://www.nih.gov/news-events/nih-research-matters/endometriosis-may-increase-type-2-diabetes-risk   XX MiniMed files FDA submission for it's first patch pump, with a planned launch next summer. To be called MiniMed fit, it would have a 300-unit insulin reservoir and would accommodate up to seven days of wear time. MiniMed also completed enrollment of a pivotal trial for a fully closed loop algorithm, which would calculate the amount of insulin a person needs throughout the day, even if they don't announce meals or count carbohydrates. Interestingly, on an investor call, the CEO acknowledged that CGMs have been their – quote – Achilles' heel for a very long time" and that their newest sensor has helped drive insulin pump growth. https://www.medtechdive.com/news/minimed-submits-new-patch-pump-for-fda-clearance/829313/ XX A new study based on national health registers in Denmark suggests starting statin treatment after a type 2 diabetes diagnosis could lower the risk of dementia, and it seems that the sooner patients did, the better. The research, published in The Lancet Regional Health, is an observational study, meaning it can find statistically relevant patterns at the population level, but doesn't necessarily explain what caused those patterns. The results, however, were interesting enough that the researchers, led by medical doctor Tummas Ternhamar of the Copenhagen University Hospital, are urging doctors to consider statin therapy when diagnosing type 2 diabetes patients. "Statins seem to be underused in patients with type 2 diabetes, despite their protective effects against cardiovascular disease." https://www.sciencealert.com/statins-linked-to-lower-dementia-risk-in-massive-type-2-diabetes-study XX Big sports news with type 1. Alezander Zverev wins Family was at the heart of Alexander Zverev's U.S. Open triumph on Sunday as the German saluted the members of his inner circle and paid a heartfelt tribute to his mother for refusing to let diabetes define his future. The ​top seed beat American Ben Shelton 6-3 7-6(2) 5-7 6-2 at Flushing Meadows to finish a spectacular year at ‌the Grand Slams in which he proved his doubters wrong by going from perennial nearly man to two-time major champion. Shortly after his victory, Zverev reserved special praise for his mother Irina, a former professional tennis player, and credited her with ensuring type 1 diabetes never limited his ambitions in life. "When your 4-year-old son is diagnosed with diabetes and doctors in the office ​tell you that life and sports will be very limited for that child, it takes a very strong mother to ​say 'my son will be whatever he wants to be'," Zverev said. "'If he wants to be a tennis player, ⁠he'll be a tennis player. If he wants to do something else, he'll do something else, but this illness will not define us'. https://www.reuters.com/sports/tennis/zverev-hails-mothers-belief-after-us-open-triumph-2026-09-13/ XX Also, shout out to Garrett Mitchell (Center field  Milwaukee Brewers) lives with Type 1 Diabetes and hit a grand slam immediately after having a failed insulin pump site. He was diagnosed with T1D at the age of 9. And I have a T1d mom friend who's known him since he was a kid. Just great to see athletes talking about failed insulin sets like they're just part of everyday life.. because they are. Btw it was the first grand slam for the brewers all year. XX The new Netflix movie The Runner is getting a bit of a side eye from some in the diabetes community… the Gal Gadot thriller features a child with type 1 but as usual, there are some weird inaccuracies. Ginger Vieria from Diabetes nerd has a great vide on this – I'll link it up: but they're saying things like Insulin Dispenser instead of pump.. and some other weird stuff.. but I've heard such bad things about this movie I'm not sure it's worth watching just for this. Ginger's video is though! https://www.youtube.com/shorts/o8cw_gEZj5s  

Dr. Ross Pelton, Director of Science & Education for Essential Formulas Incorporated, maker of Dr. Ohhira's premium probiotic products, reveals how the gut microbiome affects metabolism, appetite, weight regulation, and overall health. He emphasizes the importance of microbiome diversity, supported by eating a wide variety of plant foods rich in fiber and polyphenols, and discusses how fermented foods and postbiotic metabolites help maintain a healthy gut environment. Pelton explains Dr. Ohhira's multi-year fermentation process and the idea that postbiotics may be key health regulators. He reviews studies suggesting benefits from Dr. Ohhira's probiotics for athletic performance markers, reduced fatigue, and improved bowel regularity, and notes research showing antibiotic-related losses in gut diversity can persist for years. He also mentions a higher-dose “Reset Challenge,” a postbiotic paste concentrate, and an ME-3 product aimed at increasing glutathione.

Your primary care provider is doing their best. But there's something they may not be telling you — not because they're hiding it, but because they simply can't know everything.In this episode of Your Health University, Jamie Preston sits down with Scott Middleton — Founder and Chief Disruption Officer of Your Health — to talk about one of the most underutilized parts of the American healthcare system: specialty care. Scott shares real stories from the field that will make you rethink what you expect from your next appointment, including a patient who had been living in a nursing home for years without ever being offered a weight-loss medication that was available to her, and a lawsuit that turned on a single chest x-ray that no one thought to order.What you'll learn in this episode:Why your primary care provider legally cannot keep up with every new medication, treatment, and specialist recommendation — and what to do about itWhat GLP-1 medications are, who qualifies, and why so many eligible patients are never told they existThe standard of care around lung cancer screening for smokers — and why not knowing this can have life-altering consequencesHow to ask for a specialist referral (and what happens if your provider pushes back)Why behavioral health is one of the most under-accessed specialties in America — and how to change that for yourselfWhat "integrated care" actually looks like when it works — and what you deserve to expect from your healthcare teamYou are the CEO of your own health. This episode gives you tools to act like it. www.YourHealth.Org

Nutrition Nugget! Bite-sized bonus episodes offer tips, tricks and approachable science. This week, Jenn is talking about Retatrutide, the third-generation injectable making waves as the most powerful weight-loss drug studied yet. It targets three hormone pathways at once instead of just one or two, and early trial participants have lost staggering amounts of weight, some over 30 percent of their body weight. But is more always better? Jenn breaks down how this triple mechanism works in the body, what the research shows so far, and why it might finally help the roughly 10 percent of people who never responded to earlier GLP-1s. Still, she has been raising the same concerns since Ozempic first came onto the scene, and this new drug is no exception. Is Retatrutide the breakthrough the weight loss world has been waiting for, or just a stronger version of the same unanswered questions? Tune in to hear Jenn's full take. Like what you're hearing? Be sure to check out the full-length episodes of new releases every Wednesday. Have an idea for a nutrition nugget? Submit it here: https://asaladwithasideoffries.com/index.php/contact/ RESOURCES:Become a Happy Healthy Hub MemberJenn's Free Menu PlanA Salad With a Side of FriesA Salad With A Side Of Fries MerchA Salad With a Side of Fries InstagramOzempicAmerican Diabetes Association Retatrutide—A Game Changer in Obesity Pharmacotherapy - PMCGlucagon | HormonesInternational Journal of Molecular SciencesHyperglycemia vs. Hypoglycemia: Differences in Causes and Symptoms - GoodRxGlucagon Control on Food Intake and Energy Balance - PMCLilly Phase 3 StudyComparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials - ScienceDirectLilly - RetatrutideWhat Is Osteoarthritis? Causes, Symptoms, and Treatments - GoodRxPotential Retatrutide Benefits You Should Know About - GoodRxClinical TrialsStudy Details | NCT07165028 | A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | ClinicalTrials.govClinical TrialsStudy Details | NCT06383390 | The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)ClinicalTrials.govClinical TrialsNCT07035093 | A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain | ClinicalTrials.gov11 GLP-1 Side Effects You Should Know About - GoodRxTriple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | New England Journal of Medicine Counterfeit DrugsPeptides for Weight Loss: What They Are and How They Work - GoodRxJenn Trepeck, Nutrition Nugget, Salad With A Side Of Fries, Health Tips, Wellness Tips, Retatrutide, Glp 1, Gip, Glucagon, Weight Loss, Ozempic, Wegovy, Mounjaro, Zepbound, Tirzepatide, Semaglutide, Insulin Sensitivity, Gastric Emptying, Appetite Suppression, Blood Sugar Control, A1c, Glycated Hemoglobin, Liver Steatosis, Fatty Liver Disease, Diabetic Kidney Disease, Type 2 Diabetes, Metabolic Dysfunction, Cardiovascular Risk, Osteoarthritis, Bone Density, Muscle Loss, Body Composition, Clinical Trials, Phase Three Trials, Injectable Medication, Weight Loss Drug, Pharmaceutical Intervention, Hunger Hormone, Satiety, Nausea, Constipation, Gastrointestinal Side Effects, Compounding Pharmacy, Counterfeit Medication, Obesity Treatment, Incretin Hormone, Retatrutide Weight Loss Results, Third Generation Glp 1 Medication

GLP-1s are everywhere right now..Ozempic. Wegovy. Semaglutide. Weight loss shots. Everyone knows someone who's on one, or is wondering if they should be..And listen, I'm not anti-GLP-1. These medications can be incredibly helpful for the right person. But I am interested in the conversation we're not having enough of: why is your body struggling metabolically in the first place?.So in this episode, we're getting into what GLP-1s actually do in your body, how they affect insulin, blood sugar, appetite, digestion and metabolism, and what happens when we use them to override symptoms without asking what those symptoms might be telling us..We're also talking about the less sexy stuff—constipation, bloating, muscle loss, inflammation, insulin resistance, protein, fiber, gut health—and, because obviously I can't help myself, diet culture and our collective obsession with making bodies smaller..This isn't a “GLP-1s are bad” episode.It's a can we please understand WTF is happening in the body before we decide the body is the problem? episode..Because losing weight and getting healthier are not always the same thing..And skinny has never been a synonym for healthy..Let's get into it.

Welcome to the latest Midlife Minute. Today, I'm answering listeners' questions about cardiovascular risk, focusing on Lp(a), LDL, statins, and the changes women experience after menopause. Stay tuned for more! IN THIS EPISODE, YOU WILL LEARN: Why women should have their Lp(a) checked both before and after menopause How Lp(a) works as a risk enhancer, and how cardiovascular risk becomes more significant when elevated Lp(a) occurs alongside high LDL Why family history is particularly helpful for women with a 10-year calculated cardiovascular risk that looks reassuringly low I review the current guidelines for primary prevention Why, even though research has shown reductions in major cardiac events with GLP-1s, GLP-1s do not replace statins for lowering LDL  What a CAC score can reveal about coronary artery calcification, and what it cannot detect How AI-assisted CT angiography (such as Clearly) can map, quantify, and characterize plaque throughout the coronary branches Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website. Submit your questions to support@cynthiathurlow.com  Join other like-minded women in a supportive, nurturing community: The Midlife Pause/Cynthia Thurlow.  Purchase Cynthia's book, The Menopause Gut. Cynthia's Intermittent Fasting Transformation Book The Midlife Pause Supplement Line References: 1.  ​Lipoprotein(a) and Women's Cardiovascular Health: A Review. JACC. Advances. 2026. Michos ED, Saucier S, Mehran R, Koschinsky ML.Recent 2.  ​Sex Differences of Lipoprotein(a) Levels and Associated Risk of Morbidity and Mortality by Age: The Copenhagen General Population Study. Atherosclerosis. 2022. Simony SB, Mortensen MB, Langsted A, et al. 3. Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2022. Stone NJ, Smith SC, Orringer CE, et al.Review 4. Thirty-Year Risk of Cardiovascular Disease Among Healthy Women According to Clinical Thresholds of Lipoprotein(a). JAMA Cardiology. 2026. Nordestgaard AT, Chasman DI, Moorthy V, et al.RecentObservational 5.  ​Lipoprotein(a).The Journal of the American Medical Association. 2025. Mora S, Kronenberg  6. Clinical Practice Guideline on Lipid Management for Cardiovascular Disease Risk Reduction. Department of Veterans Affairs (2026). 2026. Paul Heidenreich, Lance Spacek, Neil Gregor, et al. Guideline 7. Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk. Journal of the American College of Cardiology. 2020. Mehta A, Virani SS, Ayers CR, et al.Observational 8. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2010. Greenland P, Alpert JS, Beller GA, et al.Guideline 9. Prevalence and Prognostic Implications of Coronary Artery Calcification in Low-Risk Women. The Journal of the American Medical Association. 2016. Kavousi M, Desai CS, Ayers C, et al.SR 10. ​Coronary Artery Calcium Scores and Risk for Cardiovascular Events in Women Classified as “Low Risk” Based on Framingham Risk Score: The Multi-Ethnic Study of Atherosclerosis (MESA). Archives of Internal Medicine. 2007. Lakoski SG, Greenland P, Wong ND, et al.Observational 11. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2019. Arnett DK, Blumenthal RS, Albert MA, et al.Guideline 12. HOPE for Rational Statin Allocation for Primary Prevention: A Coronary Artery Calcium Picture Is Worth 1000 Words. Mayo Clinic Proceedings. 2020. Orringer CE, Maki KC.Review 13. Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2020. Cho L, Davis M, Elgendy I, et al.Review 14. Health Maintenance in Postmenopausal Women. American Family Physician. 2025. Plesa M, Wong A, Katsaggelos E.Guideline 15.  ​Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT. Diabetes Care. 2024. Lingvay I, Deanfield J, Kahn SE, et al.RCT 16.  ​Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England Journal of Medicine. 2023. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.RCT 17. Long-Term Weight Loss Effects of Semaglutide in Obesity Without Diabetes in the SELECT Trial. Nature Medicine. 2024. Ryan DH, Lingvay I, Deanfield J, et al.RCT 18. Interventions for the Prevention and Management of Cardiometabolic Multiple Long-Term Conditions. Lancet. 2026. Valabhji J, Hope D, Sayed NE, et al.RecentReview 19. Glucagon‐Like Peptide‐1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta‐Analysis of Randomized‐Controlled Trials. Clinical Cardiology. 2024. Hosseinpour A, Sood A, Kamalpour J, et al.SR 20. ​FDA Orange Book. FDA Orange Book. 2026. 21. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026. Diabetes Care. 2026. American Diabetes Association Professional Practice Committee for Diabetes*.RecentGuideline 22. Premature Coronary Artery Disease in Women: Sex-Specific Risk Factors, Pathogenetic Mechanisms and Clinical Implications. Annals of Medicine. 2026. Li F, Hong D, Yang M, et al.RecentReview 23. Cardiovascular Disease Risk Factors in Women: The Impact of Race and Ethnicity: A Scientific Statement From the American Heart Association. Circulation. 2023. Mehta LS, Velarde GP, Lewey J, et al.Guideline 24. Preventing CVD in Women: Common Questions and Answers. American Family Physician. 2023. Westfall E, Viere AB, Genewick JE.Review 25. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation. 2020. El Khoudary SR, Aggarwal B, Beckie TM, et al.Guideline

Send us Fan MailIs weight loss really a matter of willpower—or have we misunderstood the biology behind hunger?Bracha Banayan, FNP-BC, joins Joey Pinz to explore the rapidly evolving world of GLP-1 medications, metabolic health, food noise, cravings, and sustainable weight loss. Drawing from her clinical experience and personal journey, Bracha explains why traditional advice to “eat less and try harder” often fails—and why that failure should not be confused with laziness.The conversation moves beyond weight loss into the brain's reward system and the potential relationship between GLP-1s, alcohol, smoking, shopping, and other compulsive behaviors. Bracha also explains why these medications should never become an excuse to ignore strength training, muscle preservation, nutrition, and lasting habit change.The discussion becomes deeply personal as Bracha shares how remedial classes shaped her persistence, why entrepreneurship taught her difficult lessons about leadership, and how leaving Orthodox Judaism led her toward a broader spiritual path. She also reveals how egg freezing changed her relationship with fear, courage, vulnerability, and regret.This is a provocative conversation about biology, personal responsibility, longevity, identity, and what sustainable transformation truly requires.Top Three Highlights

The U.K. announces sanctions on West Bank settlements, Canada's retaliatory tariffs on $20 billion in U.S. goods take effect, Haaretz reports that Netanyahu received advanced warning before Oct. 7, Rubio kicks off a three-day tour of Colombia, Ecuador and Peru, thieves steal paintings worth €9M from France's Renoir Museum, Ukraine's top prosecutor resigns amid an ongoing corruption probe, Smithsonian Secretary Lonnie Bunch announces his retirement, OpenAI's top scientist warns nobody is prepared for the continued rise in AI, Nepal seeks $20 million in flood aid from "polluting economies," and Novo Nordisk reports that Semaglutide cuts obesity in 40% of kids under 12. Sources: Verity.News

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we unveil a series of transformative strides in drug approvals, clinical trials, and regulatory landscapes that are reshaping the future of patient care. AstraZeneca's camizestrant, now branded as Etcamah, has received FDA approval for treating ESR1-mutated hormone receptor-positive, HER2-negative advanced breast cancer. This approval is a testament to the potential of selective estrogen receptor degraders (SERDs) in oncology. The Phase 3 trial results highlight camizestrant's efficacy when combined with CDK4/6 inhibitors, offering a tailored therapeutic strategy for patients with ESR1 mutations. Such advancements in personalized oncology are steering the industry toward more precise treatment paradigms. Complementing this approval, Guardant Health's Guardant360 CDx has been sanctioned as a companion diagnostic tool for camizestrant. The liquid biopsy-based method precisely identifies ESR1 mutations, underscoring the growing reliance on precision diagnostics in cancer management. As precision medicine continues to evolve, integrating diagnostics with therapeutics becomes crucial in achieving optimal patient outcomes. Bristol Myers Squibb has made headlines with its CAR-T cell therapy, arlocabtagene autoleucel, showing efficacy in its Phase 3 trial for GPRC5D-targeted relapsed or refractory multiple myeloma. This advancement reflects the burgeoning application of cell-based treatments in hematological malignancies and signals a shift towards personalized immunotherapy strategies promising improved patient outcomes. On a related note, Brainchild Bio's significant $116 million fundraising initiative aims to advance CAR-T therapies tailored for childhood brain cancers. This development highlights the potential of CAR-T technology beyond hematologic cancers and indicates an intensified focus on pediatric oncology therapeutics. In regulatory news, Shionogi's cefiderocol has gained approval from Australia's Therapeutic Goods Administration (TGA) for combating carbapenem-resistant gram-negative bacterial infections. Cefiderocol addresses critical needs in combating multidrug-resistant pathogens, particularly in urinary tract infections, and highlights ongoing global efforts to tackle antimicrobial resistance. Clinical trials continue to yield promising outcomes. Pharvaris' deucrictibant showcased positive results in its Phase 3 trial for hereditary angioedema by effectively targeting the bradykinin B2 receptor. Novo Nordisk's semaglutide (Wegovy) demonstrated remarkable efficacy in reducing obesity among children during its Phase 3 trials. These results emphasize continued innovation in treating metabolic disorders and rare diseases by leveraging small molecule therapeutics and receptor modulators. Not all developments have been positive. Novartis and Ionis Pharmaceuticals faced setbacks with pelacarsen failing to meet endpoints in a Phase 3 trial aimed at reducing major cardiovascular events despite lowering lipoprotein(a). This underscores the challenges of translating promising biomarkers into effective therapeutic interventions. Regulatory challenges were also observed as American Regent recalled batches of epinephrine due to contamination issues, and Boston Scientific recalled spinal cord implants linked to serious injuries. These instances underscore the importance of stringent quality control and regulatory compliance to ensure patient safety. Meanwhile, Amgen's DLL3-targeted therapy, Imdelltra, achieved an overall survival win in a first-line setting for small cell lung cancer (SCLC), although specific numerical results were not disclosed. This bispecific antibody could set a new standard for early intervention in SCLC, emphasizing the potential of targeted therapies in improving survival rates for aggressive cancers. In other advancements, Roche continues to dominate neurology with top positions in corporate reputation rankings within this therapeutic area. This accolade reflects Roche's commitment to innovation and patient-centric approaches to managing neurological disorders. As these developments unfold across various domains of pharmaceutical innovation and regulation, they collectively signal a dynamic era for the industry marked by rapid scientific progress and evolving treatment strategies. The implications are profound, offering potential improvements in patient outcomes through more targeted therapies while highlighting challenges such as clinical trial failures that necessitate continued diligence in drug development strategies. As these trends unfold, they hold promise for significant advancements in treatment efficacy and safety across various therapeutic areas. Thank you for tuning into Pharma Daily. Stay informed about the latest industry developments as we continue to explore the dynamic landscape of pharmaceutical innovations together.Support the show

Send us Fan MailPeptides are everywhere right now—but are they truly the future of women's health, or just another wellness trend?In this episode of It's Hertime, Cody is joined once again by Functional Diagnostic Nutrition Practitioner, women's hormone expert, and peptide educator Bria Gadd. Together, we break down what peptides actually are, how they work in the body, and how to know whether they may be the right tool for you.Together they talk about GLP-1 medications like Semaglutide, Tirzepatide, and Retatrutide—and why using them well involves so much more than simply losing weight. We also explore peptides being used for healing and recovery, mitochondrial health, healthy aging, skin, hair, libido, and hormone support.Most importantly, this conversation isn't about finding another shortcut. Peptides can be powerful tools, but they cannot replace nourishing your body, protecting your muscle, managing stress, getting enough sleep, and building a lifestyle that supports your health.In this episode, we cover:• What peptides are and why they're suddenly everywhere• How peptides differ from hormones and traditional medications• Who may—or may not—be a good candidate• Semaglutide, Tirzepatide, and Retatrutide beyond weight loss• How to protect muscle while using a GLP-1• Peptides for recovery, longevity, skin, hair, and libido• Why lifestyle and nervous-system regulation still matter• Potential risks, side effects, and the importance of medical supervision• How to recognize a trustworthy provider and high-quality source• Where peptide therapy may be headed next in women's medicineCurious about peptides and want personalized guidance? You can learn more about working with Cody here.Want to connect with Bria and learn more from her? Visit Bria's website, follow her on Instagram at @bria_period_whisperer, and explore her coaching programs. You can also listen and subscribe to The Period Whisperer Podcast on Apple Podcasts or Spotify.This episode is for educational purposes only and is not intended to diagnose, treat, or replace individualized medical care.Did you learn something new today? Be sure to subscribe to this podcast and share this episode with all the girls you love. We would appreciate it if you'd also leave us a rating and review on iTunes.Want to join our Mixhers Girl community and keep this conversation going? We'd love to hear your thoughts, feelings and experiences! Join us HERE!Join Mixhers email list and be the first to have access to new products and be the girl in the know!Follow Cody Instagram:@codyjeansanders

MASH is often called a silent disease, but its impact can be significant. Join Dr. Gerry Clancy and University of Iowa liver specialists Dr. Marta Tejedor Bravo and Dr. Alan Gunderson as they explore risk factors, screening, disease progression, and emerging therapies that are reshaping care for patients with metabolic liver disease. Liver Wellness | The University of Iowa Iowa Liver Wellness Symposium: Cirrhosis Care in Motion 2026 5k Race - Run for Your Liver, Run for Your life (and last year's video Run for Your Liver, Run for Your Life) Episode Transcript CE Credit Available Host: Gerard Clancy, MD Senior Associate Dean for External Affairs Professor of Psychiatry and Emergency Medicine University of Iowa Carver College of Medicine Guests: Alan E. Gunderson, MD Clinical Associate Professor of Internal Medicine-Gastroenterology and Hepatology University of Iowa Carver College of Medicine Marta Tejedor Bravo, MD, MSc, PhD Clinical Associate Professor of Internal Medicine-Gastroenterology and Hepatology University of Iowa Carver College of Medicine Financial Disclosures:   Dr. Clancy, Dr. Tejedor Bravo, and the members of the Rounding@IOWA planning committee have disclosed no relevant financial relationships. Dr. Gunderson has disclosed the following relationships: CymaBay Therapeutics, Inc.; GigaGen, Inc.; LISCure Biosciences, Inc. - Sponsored Research Relevant financial relationships have been mitigated. Nurse: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this activity for a maximum of 1.00 ANCC contact hour. Pharmacist and Pharmacy Tech: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this knowledge-based activity for a maximum of 1.00 ACPE contact hours. Credit will be uploaded to the NABP CPE Monitor within 60 days after the activity completion. Pharmacists must provide their NABP ID and DOB (MMDD) to receive credit. JA0000310-0000-26-058-H01 Physician: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other Health Care Providers: A certificate of completion will be available after successful completion of the course. (It is the responsibility of licensees to determine if this continuing education activity meets the requirements of their professional licensure board.) References:  Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, Kleiner DE, Loomba R. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023 May 1;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323. Epub 2023 Mar 17. PMID: 36727674; PMCID: PMC10735173. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024 Sep;81(3):492-542. doi: 10.1016/j.jhep.2024.04.031. Epub 2024 Jun 7. PMID: 38851997. Younossi ZM, Zelber-Sagi S, Lazarus JV, Wong VW, Yilmaz Y, Duseja A, Eguchi Y, Castera L, Pessoa MG, Oliveira CP, El-Kassas M, Tsochatzis E, Fan JG, Spearman CW, Tacke F, Castellanos Fernandez MI, Alkhouri N, Schattenberg JM, Romero-Gómez M, Noureddin M, Allen AM, Ong JP, Roberts SK, Shubrook JH, Burra P, Kohli R, Kautz A, Holleboom AG, Lam B, Isaacs S, Macedo P, Gastaldelli A, Henry L, Ivancovsky-Wajcman D, Nader F, de Avila L, Price JK, Mark HE, Villota-Rivas M, Barberá A, Kalligeros M, Gerber LH, Alqahtani SA. Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis. Gastroenterology. 2025 Oct;169(5):1017-1032.e2. doi: 10.1053/j.gastro.2025.02.044. Epub 2025 Apr 11. PMID: 40222485. Mladenić K, Lenartić M, Marinović S, Polić B, Wensveen FM. The "Domino effect" in MASLD: The inflammatory cascade of steatohepatitis. Eur J Immunol. 2024 Apr;54(4):e2149641. doi: 10.1002/eji.202149641. Epub 2024 Feb 5. PMID: 38314819. Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, Anstee QM, Abdelmalek MF, Younossi Z, Baum SJ, Francque S, Charlton MR, Newsome PN, Lanthier N, Schiefke I, Mangia A, Pericàs JM, Patil R, Sanyal AJ, Noureddin M, Bansal MB, Alkhouri N, Castera L, Rudraraju M, Ratziu V; MAESTRO-NASH Investigators. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000. PMID: 38324483. Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, Cali AMG, Bugianesi E, Rinella ME, Roden M, Ratziu V; ESSENCE Study Group. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025 Jun 5;392(21):2089-2099. doi: 10.1056/NEJMoa2413258. Epub 2025 Apr 30. PMID: 40305708.  

One Big Question Podcast-"Unlocking Health: The Semaglutide Revolution"Semaglutide is a 31-amino-acid GLP-1 receptor agonist, engineered from a natural gut hormone into a once-weekly peptide. Under three brand names, Ozempic, Wegovy, and Rybelsus, it now carries some of the strongest human outcome evidence in metabolic medicine.[1][2]This unit traces the discovery and the approval timeline, defines the key terms you will meet across the course, and sets an honest evidence picture before any of the deeper biology. Everything here is education, not medical advice.#DontMissThis⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ #NewEpisode⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ #VideoPodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#nowstreaming ⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#podcastlife⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#PodcastVibes⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#PodcastClip⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#PodcastEpisode⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#PodcastStudio⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#NewEpisode⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#OnTheMic⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#PodcastCommunity⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#VideoPodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#ContentCreator⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#CreatorMode⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#DigitalMedia⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#ReelsPodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#ShortsPodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#ViralPodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#TrendingNow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#FYP⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#ForYou⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#ExplorePage⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#NowStreaming⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#WatchThis⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#MustWatch⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#TapIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#DontMissThis⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#MediaCulture⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#TalkShowVibes⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#OnAirEnergy⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#RealTalk⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#CreativeCommunity⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#BehindTheMic⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#InTheStudio⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠© 2026 K.L.P Entertainment Filmworks© 2026 K.L.P Studios

Semaglutide is a 31-amino-acid GLP-1 receptor agonist, engineered from a natural gut hormone into a once-weekly peptide. Under three brand names, Ozempic, Wegovy, and Rybelsus, it now carries some of the strongest human outcome evidence in metabolic medicine.[1][2]This unit traces the discovery and the approval timeline, defines the key terms you will meet across the course, and sets an honest evidence picture before any of the deeper biology. Everything here is education, not medical advice.#DontMissThis⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ #NewEpisode⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ #VideoPodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#nowstreaming ⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#podcastlife⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#PodcastVibes⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#PodcastClip⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#PodcastEpisode⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#PodcastStudio⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#NewEpisode⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#OnTheMic⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#PodcastCommunity⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#VideoPodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#ContentCreator⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#CreatorMode⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#DigitalMedia⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#ReelsPodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#ShortsPodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#ViralPodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#TrendingNow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#FYP⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#ForYou⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#ExplorePage⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#NowStreaming⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#WatchThis⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#MustWatch⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#TapIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#DontMissThis⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#MediaCulture⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#TalkShowVibes⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#OnAirEnergy⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#RealTalk⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#CreativeCommunity⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#BehindTheMic⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#InTheStudio⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠© 2026 K.L.P Entertainment Filmworks© 2026 K.L.P Studios

A hundred million Americans don't have a primary care provider. For most healthcare systems, that's a problem. For Scott Middleton, it's proof that the whole model needs to change.Scott, founder and Chief Disruption Officer at Your Health, joins Jamie for an unfiltered conversation about what wellness actually is — and why it's not the same as primary care. Your Health's wellness program has exploded from zero to 4,100 patients in just two years, and Scott is just getting started. From GLP-1s and hormone replacement to peptides and the controversial South Carolina ruling that tried to silence physicians, Scott holds nothing back — and makes clear he's willing to take the fight to court.In this episode:Why wellness is a specialty — not an alternative to primary care — and why the distinction changes everything about how patients should seek careThe South Carolina Board of Medical Examiners' peptide ruling, why Scott believes it violates the First Amendment, and what he plans to do about itHow clinical pharmacists and nurse practitioners are filling the gaps physicians are being pressured to leaveScott's own transformation: from 425 pounds to 216, cholesterol from 280 to 189, and what specific peptides and protocols drove those resultsWhy employers like Bank of America — spending $2 billion a year on employee health — are the sleeper stakeholders in the wellness revolutionIf you've been told to "come back when something's wrong," this episode is the permission slip to demand something better. www.YourHealth.Org

Exercise, Recovery, Relaxation—and Muscle as the Key to Healthy Aging: Nutritionist Leyla Muedin discusses science-backed wellness trends that pair exercise with effective recovery and deliberate relaxation to support performance, resilience, and healthy aging, noting benefits such as fewer overuse injuries, better sleep, steadier energy, and improved adherence. She highlights relaxation practices (breathwork, meditation, gentle yoga, outdoor time, massage, consistent sleep routines) and encourages making recovery part of daily life, including creating home or community “wellness spaces” like pools for gentle movement and stress reduction. She emphasizes sustainable habits supported by tools like wearables and heart-rate variability tracking. The episode then frames muscle as a “longevity secret weapon,” explaining its roles in metabolism, glucose storage, insulin sensitivity, inflammation control, and joint stability, citing the PURE study on grip strength and mortality, warning about sarcopenia, and recommending strength training, higher and well-distributed protein intake with age due to anabolic resistance, plus adequate sleep and recovery.

Thinking about trying a GLP-1 but not sure if you need a full dose? What exactly is microdosing, and does it really work? In this episode, I'm joined by Dr. Tyna Moore to talk about GLP-1s, microdosing, weight loss, muscle loss, menopause, hormone replacement therapy, and what's next for peptide therapy.

GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro have reshaped the weight-loss landscape almost overnight — but the way they're often prescribed leaves people under-fueled, losing muscle, and going it alone. In this episode of The Coaching Lab, host Leigh Baker sits down with National Board Certified Health & Wellness Coach Erin Chain and triple-board-certified physician Dr. Sheri Poznanovic of Optin Health & Nutrition to unpack what's really happening in the GLP-1 era — and where health and wellness coaching fits into the care plan.Together they explore why so many people on GLP-1s aren't eating or hydrating enough, how rapid weight loss can mask dangerous muscle mass loss, and why a "prescribe-and-disappear" model falls short. Dr. Poznanovic explains the multidisciplinary approach the Obesity Medicine Association recommends — combining medication, nutrition, body composition testing, VO2 max assessment, and coaching — while Erin shares real-world stories of clients navigating low energy, food noise, protein gaps, medication interactions, and the stigma of being on a GLP-1.Whether you're a coach, a clinician, an employer weighing GLP-1 coverage, or someone considering these medications yourself, this conversation offers a grounded, human look at doing weight loss in a way that protects strength, health span, and quality of life — not just the number on the scale.In this episode: • Why coaching alongside a GLP-1 changes outcomes • The under-eating and muscle-loss risks no one warns you about • Protein targets, carbs, and why "anti-carb" advice backfires • Body composition and VO2 max testing in weight management • Medication interactions as you lose weight • Navigating stigma and the joy of food • What employers and coaches should know before adding GLP-1sCoaches: Explore CE credits at catalystcoachinginstitute.com Employers: Learn about Catalyst Coaching's GLP-Whole offering — results@catalystcoaching360.com Join us this fall at the Rocky Mountain Coaching Retreat & Symposium: catalystcoachinginstitute.com/retreatInfo re earning your health & wellness coaching certification, annual Rocky Mountain Coaching Retreat & Symposium & more via https://www.catalystcoachinginstitute.com/ Best-in-class coaching for Employers, EAPs & wellness providers https://catalystcoaching360.com/Tap into the home of the (freely available) Not Done Yet! articles on unlocking life's 2nd half here.YouTube Coaching Channel https://www.youtube.com/c/CoachingChannelContact us: Results@CatalystCoaching360.comTwitter: @Catalyst2ThriveWebsite: CatalystCoaching360.comIf you are a current or future health & wellness coach, please check out our Health & Wellness Coaching Community on Facebook: https://www.facebook.com/groups/278207545599218.  This is a wonderful group if you are looking for encouragement, ideas, resources and more. 

Research suggests that more than half of Americans could benefit from taking a GLP-1 RA medication. The drugs were originally designed to help manage type two diabetes, but in 2024, the Food and Drug Administration approved one GLP-1, Semaglutide, for weight loss. With that approval came a spike in prescriptions for the drugs, and a spike in calls related to GLP-1s to poison control centers. That's the focus of this episode of Stats and Stories with guests Jordan and Robert Miller. Jordan Miller is a post-baccalaureate student, double majoring in statistics and data science and mathematics at UT San Antonio. Robert Miller is a specialist in poison information with the South Texas Poison Center at UT San Antonio. 

Semaglutide, tirzepatide and retatrutide are often spoken about as though they are simply different versions of the same thing. They are not—and Kim Constable's personal experience with each one was very different. In this episode, Kim moves beyond receptor science and shares what exploring all three compounds was actually like for her: the benefits she noticed, the side effects she experienced, the results that surprised her and which option she personally preferred. Kim's interest in GLP-1s originally extended far beyond weight loss. As she moved further into menopause, she was struggling with persistent gluteal tendinopathy, joint pain, digestive discomfort, bloating, morning headaches, brain fog, broken sleep and repeated nighttime bathroom trips. Foods she had eaten comfortably for years—including beans, lentils and cruciferous vegetables—had become increasingly difficult to tolerate. After hearing GLP-1s discussed in relation to inflammation, digestion, sleep and metabolic health, Kim began exploring semaglutide. She later tried tirzepatide and retatrutide, allowing her to compare her personal response to all three. The compounds target different combinations of pathways: • Semaglutide primarily targets GLP-1 • Tirzepatide targets GLP-1 and GIP • Retatrutide targets GLP-1, GIP and glucagon Kim explains why those differences matter and why a compound that feels transformative for one person may feel far less effective—or create more unwanted effects—for another. Inside this episode: • Why Kim first became interested in GLP-1s during menopause • The difference between semaglutide, tirzepatide and retatrutide • Why more receptor activity does not automatically mean better results • Kim's personal experiences with appetite and food noise • The differences she noticed in inflammation and physical pain • Changes she observed in digestion, headaches, brain fog and sleep • How each experience affected fat loss and weight maintenance • Why she initially felt hesitant to admit that easier fat loss appealed to her • The judgment surrounding GLP use • Fatigue, headaches and digestive slowing • An unexpected herpes flare-up pattern Kim noticed while taking semaglutide • Why anecdotal observations do not prove clinical causation • The benefits that felt meaningful to Kim and the effects that did not • Which of the three she personally preferred • Why another person's experience or dose should never become your protocol This episode is not intended to tell listeners which compound they should choose. It is a candid account of Kim's individual experience with three different compounds and why she believes the decision is far more nuanced than simply asking which one is “strongest.” This episode contains candid discussion of genital herpes, digestive symptoms and medication side effects. Kim's experience is personal. Nothing discussed should be treated as proof that another person will experience the same benefits, risks or side effects. This podcast is for educational and informational purposes only. Kim is not a doctor or licensed medical practitioner. Nothing in this episode should be interpreted as medical advice, a diagnosis, prescribing guidance or instructions for purchasing, reconstituting, dosing or administering any compound. Always consult an appropriately qualified healthcare professional before beginning, stopping or changing any medication or treatment. Some compounds discussed may be prescription medicines or investigational products depending on jurisdiction and current regulatory status. ✨ Follow Kim Constable online for more real talk and daily motivation:

Primary care physicians Kate, Mark, Henry and Gary discuss 4 new studies that could change your practice: treatments for hyperemesis gravidarum, calcium and vitamin D to prevent falls and fractures in older adults, the first oral PCSK9 inhibitor, and oral semaglutide to treat dementia .The John Hickner Memorial fund at MSU: https://give.msu.edu/?sid=17374 Hyperemesis gravidarum treatments: https://pubmed.ncbi.nlm.nih.gov/41478546/ Supplementing with calcium or vitamin D: https://pubmed.ncbi.nlm.nih.gov/42161415/ Oral PCSK-9 enlicitide:  https://pubmed.ncbi.nlm.nih.gov/41879224/ Cochrane review of PCSK-9s: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011748.pub3/full Semaglutide for dementia: https://pubmed.ncbi.nlm.nih.gov/41865758/

Who on the team is on a GLP1 medication, why they started it and how's it going? An honest discussion. See omnystudio.com/listener for privacy information.

Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial The American Journal of Psychiatry Accumulating preclinical and observational evidence suggests that glucagon-like peptide-1 receptor agonists, including semaglutide, reduce alcohol consumption. This phase 2 double-blind, randomized, parallel-arm trial evaluated the effects of oral semaglutide on alcohol craving and consumption among treatment-seeking adults with alcohol use disorder (AUD).  It found that semaglutide did not significantly reduce laboratory-assessed craving or drinks per day compared with placebo but significantly reduced heavy drinking days. Semaglutide also significantly reduced drinks per drinking day, naturalistic alcohol craving, and cannabis use days. Semaglutide reduced alcohol-related consequences at a significantly greater rate than placebo. Significantly more participants in the semaglutide group than the placebo group reduced their risk drinking level by one or more levels. These findings confirm previous results among non–treatment seekers with less severe AUD and suggest that continued development of semaglutide for AUD is warranted.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM  

Today we're going to compare the two available forms of semaglutide: the once-weekly injection and the once-daily tablet. Both contain semaglutide, but they differ significantly in how the medication is absorbed, how often it's taken, the instructions for administration, approved uses, storage requirements, and cost. We'll also discuss the technology that makes oral semaglutide possible, why the tablet has specific timing requirements, and which option may be a better fit depending on your health history and lifestyle. Read the Full Episode Transcript: https://pepties.com/semaglutide-injection-vs-tablet-which-one-is-right-for-you/ Related Links/Products Mentioned: Peptide Podcast Partners Page https://pepties.com/partners/ Buy Peptides online at BioLongevity Labs: Use our link and enter COUPON CODE: PEPTIDEPODCAST  at checkout to receive 15% off your total order:  https://go.biolongevitylabs.com/SH5C Momentous Supplements (we use Creatine, Vital Aminos, Whey Protein) https://crrnt.app/MOME/OqGQOxGA LMNT – More Salt, Not Less.  https://elementallabs.refr.cc/default/u/johnjavit Thorne Supplements (we use Omega-3 with CoQ10, Red Yeast Rice, Zinc) https://get.aspr.app/SH1KvW Organifi Creatine and Shilajit Gummies http://rwrd.io/rlbkajm?c MitoZen (methylene blue for Cognitive Function, Anti-Aging, Mental Clarity) https://www.mitozen.com/ref/cnlwiztypt/ For skin and hair health (Copper Tripeptide-1)  Visit Luminose by Entera for an exclusive offer for Peptide Podcast listeners!  ** Promo code PEPTIDEPODCAST at checkout for 10% off an order or 10% off the first month of a subscribe-and-save. ** https://www.enteraskincare.com/?rfsn=8906839.f93c72 NAD+ Push Patch: https://www.pushpatch.com/

Everyone in this market is optimizing for the wrong thing. Consumers want the most weight loss for the cheapest price, and up to 40% of what they're losing is muscle.My guests this week are Nicholas Syhler, a former cardiologist who left his residency to work upstream of the heart attacks he was treating, and Paul Elsass, an exercise physiologist who spent years in startup land before landing on the one root cause nobody had solved. Their company, Embla, runs a coach-first GLP-1 program out of Copenhagen with peer-reviewed data on almost 5,000 patients showing 55% less medication and the same weight loss outcomes seen in clinical trials.We get into why the drug was never designed to shut off hunger, why members can sit on a quarter milligram of semaglutide for months instead of escalating every 30 days, and the claims data suggesting aggressive dosing is quietly driving up MSK spend. We also cover why they built the model around self-funded employers rather than direct-to-consumer, what one bundled price under $500 a month actually includes, and their plan to move from weight loss into full cardiometabolic care with deprescribing as the goal.If you're evaluating a GLP-1 strategy for 2027, this one reframes the question. Tune in."We were seeing four to six pounds per week. That's way too much. It should be one to two." — Nicholas SyhlerThank you to our 2026 sponsors!ParetoHealth: ParetoHealth empowers midsize employers with a long-term solution to reduce volatility and lower overall health benefits costs. Visit https://www.paretohealth.com/fully-insured-vs-self-funding-with-paretohealth-spencer-podcast/?utm_source=youtube&utm_medium=referral&utm_campaign=SelfFundedwSpencer to learn more.Samaritan Fund: A program that connects those who need help to the support they need. We are proud to offer the Samaritan Fund Program. Visit SamaritanFundProgram.com to learn more.Vālenz Health: We're Vālenz Health, your partner in improving health literacy, reducing plan spend, and delivering high-value healthcare. Visit ValenzHealth.com to learn more.Imagine360: Imagine360 helps self-funded employers save on healthcare with smarter health plans. Cut expenses by 20-30% with custom solutions. Contact us today at Imagine360.com.Chapters:(00:00:00) Intro: Meet Embla(00:01:30) From Cardiology Residency to Quitting Medicine(00:05:56) Reading the First Line on the Label(00:07:07) Losing Weight Too Fast: The Muscle Problem(00:08:34) Why "Eat Less, Move More" Fails(00:12:43) Coach First, Clinician Second(00:14:19) A Quarter Milligram for Four Months(00:16:52) Semaglutide vs. Tirzepatide(00:19:29) The MSK Claims Nobody Saw Coming(00:22:17) Why Self-Funded Employers, Not Consumers(00:25:09) Where the Name Embla Comes From(00:27:28) One Price, Everything Included(00:30:42) Learning About PBMs the Hard Way(00:34:43) Deprescribing and Cardiometabolic Care(00:42:30) Why America Makes This Harder(00:46:30) The Three Behavioral Levers(00:49:27) How the Program Actually Rolls Out(00:54:14) Diet, Fasting, and Food Quality(00:57:10) The Moonshot(01:00:59) Closing ThoughtsKey Links for Social:@SelfFunded on YouTube for video versions of the podcast and much more - https://www.youtube.com/@SelfFundedListen/watch on Spotify - https://open.spotify.com/show/1TjmrMrkIj0qSmlwAIevKA?si=068a389925474f02Listen on Apple Podcasts - https://podcasts.apple.com/us/podcast/self-funded-with-spencer/id1566182286Follow Spencer on LinkedIn - https://www.linkedin.com/in/spencer-smith-self-funded/Follow Spencer on Instagram - https://www.instagram.com/selffundedwithspencer/

Everyone in this market is optimizing for the wrong thing. Consumers want the most weight loss for the cheapest price, and up to 40% of what they're losing is muscle.My guests this week are Nicholas Syhler, a former cardiologist who left his residency to work upstream of the heart attacks he was treating, and Paul Elsass, an exercise physiologist who spent years in startup land before landing on the one root cause nobody had solved. Their company, Embla, runs a coach-first GLP-1 program out of Copenhagen with peer-reviewed data on almost 5,000 patients showing 55% less medication and the same weight loss outcomes seen in clinical trials.We get into why the drug was never designed to shut off hunger, why members can sit on a quarter milligram of semaglutide for months instead of escalating every 30 days, and the claims data suggesting aggressive dosing is quietly driving up MSK spend. We also cover why they built the model around self-funded employers rather than direct-to-consumer, what one bundled price under $500 a month actually includes, and their plan to move from weight loss into full cardiometabolic care with deprescribing as the goal.If you're evaluating a GLP-1 strategy for 2027, this one reframes the question. Tune in."We were seeing four to six pounds per week. That's way too much. It should be one to two." — Nicholas SyhlerThank you to our 2026 sponsors!ParetoHealth: ParetoHealth empowers midsize employers with a long-term solution to reduce volatility and lower overall health benefits costs. Visit https://www.paretohealth.com/fully-insured-vs-self-funding-with-paretohealth-spencer-podcast/?utm_source=youtube&utm_medium=referral&utm_campaign=SelfFundedwSpencer to learn more.Samaritan Fund: A program that connects those who need help to the support they need. We are proud to offer the Samaritan Fund Program. Visit SamaritanFundProgram.com to learn more.Vālenz Health: We're Vālenz Health, your partner in improving health literacy, reducing plan spend, and delivering high-value healthcare. Visit ValenzHealth.com to learn more.Imagine360: Imagine360 helps self-funded employers save on healthcare with smarter health plans. Cut expenses by 20-30% with custom solutions. Contact us today at Imagine360.com.Chapters:(00:00:00) Intro: Meet Embla(00:01:30) From Cardiology Residency to Quitting Medicine(00:05:56) Reading the First Line on the Label(00:07:07) Losing Weight Too Fast: The Muscle Problem(00:08:34) Why "Eat Less, Move More" Fails(00:12:43) Coach First, Clinician Second(00:14:19) A Quarter Milligram for Four Months(00:16:52) Semaglutide vs. Tirzepatide(00:19:29) The MSK Claims Nobody Saw Coming(00:22:17) Why Self-Funded Employers, Not Consumers(00:25:09) Where the Name Embla Comes From(00:27:28) One Price, Everything Included(00:30:42) Learning About PBMs the Hard Way(00:34:43) Deprescribing and Cardiometabolic Care(00:42:30) Why America Makes This Harder(00:46:30) The Three Behavioral Levers(00:49:27) How the Program Actually Rolls Out(00:54:14) Diet, Fasting, and Food Quality(00:57:10) The Moonshot(01:00:59) Closing ThoughtsKey Links for Social:@SelfFunded on YouTube for video versions of the podcast and much more - https://www.youtube.com/@SelfFundedListen/watch on Spotify - https://open.spotify.com/show/1TjmrMrkIj0qSmlwAIevKA?si=068a389925474f02Listen on Apple Podcasts - https://podcasts.apple.com/us/podcast/self-funded-with-spencer/id1566182286Follow Spencer on LinkedIn - https://www.linkedin.com/in/spencer-smith-self-funded/Follow Spencer on Instagram - https://www.instagram.com/selffundedwithspencer/

Imagine your spouse or significant other has been diagnosed with MS...shortly after you were diagnosed with stage IV colon cancer, and given just a 15% chance of survival. All of a sudden, the roles of patient and care partner are up for grabs -- and they change with almost daily frequency.  That's exactly the scenario my guest, Kathleen Silva, faced. Kathleen is joining me to discuss how she and her husband, Rick, survived and thrived amid that frightening chaos. (Spoiler alert -- no one died!)  We'll also tell you about an investigational drug that's the first to promise neuroprotection during an MS relapse. We're sharing study results that show people with MS who meet the medical criteria aren't jumping on the GLP-1 bandwagon. We'll provide compelling evidence for anyone with MS to quit smoking.  And we're breaking down the results of a study that analyzed mortality rates in cases where MS was listed as the underlying cause of death. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: When the roles of patient and care partner get turned upside down and inside out  :22 The FDA green lights clinical trials for an investigational drug that promises neuroprotection during an MS relapse   1:08 People living with MS who meet the medical criteria aren't jumping on the GLP-1 bandwagon   5:43 Study results provide startling evidence for quitting smoking if you're living with MS   8:34 In spite of highly effective DMTs, mortality rates for deaths in which MS is listed as the underlying cause are increasing  14:05 Kathleen Silva takes us through the harrowing time in her life when her husband, Rick, was diagnosed with MS shortly after she had been diagnosed with Stage 4 colon cancer and given just a 15% chance of surviving   19:23  Share this episode  35:12 Next week  36:31 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/468 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes at www.RealTalkMS.com STUDY: Use of Semaglutide and Tirzepatide Among People with Multiple Sclerosis https://journals.sagepub.com/doi/10.1177/13524585261442033 STUDY: Impact of Tobacco and Alcohol Consumption on Disease Progression and MRI In People With Multiple Sclerosis: Results of the Prospective Cohort Study NationMS https://journals.sagepub.com/doi/10.1177/17562864261464304 STUDY: Racial and Ethnic Trends and Comorbidity Patterns in Multiple Sclerosis Mortality https://www.neurology.org/doi/10.1212/WN9.0000000000000148 REGISTER: ECTRIMS Patient Community Day https://ectrimspatientcommunity.eu JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on X, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 468 Guest: Kathleen Silva Privacy Policy

What actually happens to a patient a year into real, supervised peptide therapy? In the final episode of our peptides series, Dr. Melissa Jones and host Jamie Preston close the loop on the story that opened this whole series — and get honest about what changed, what didn't, and what every provider and patient still needs to know. This episode goes beyond the science into the human side of the story: what it actually feels like when chronic pain resolves, when weight loss becomes life-changing rather than cosmetic, and when a skeptical clinician becomes one of the most passionate advocates in the building. Jamie also shares his own journey — turning 50, managing diabetes, and reaching his goal weight — as a real example of what supervised, responsible care can look like over time. In this episode, you'll hear: An update on the chronic pain patient from Episode 1 — where he is now, and what's kept his results sustainable What the actual clinical data shows about supervised BPC-157 therapy, and where its limits are Why GLP-1 success is about far more than the number on the scale — confidence, mobility, and mental health The advice Dr. Jones gives new providers who feel nervous bringing up peptides with patients The single biggest myth about peptides she wants to put to rest for good The three things every patient should understand before they ever start a peptide This is the episode that ties the whole series together — not as a sales pitch for peptides, but as a case for doing this the right way, with the right people, for the right reasons. It's the last episode in this run, but it won't be the last time we talk about this. www.YourHealth.Org

To achieve optimal outcomes for patients, it is not only the individual efforts of clinicians that matter in achieving optimal outcomes for our patients. Having a system that supports and facilitates those efforts is essential. In this special episode, Neil Skolnik speaks with Nihar Desai about the challenges of managing chronic kidney disease and diabetes. This special episode is sponsored with support from Bayer. Please listen to the episodes by clicking on the podcast player below or by freely subscribing to DOC Updates via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Nihar Desai, MD, MPH, Associate Professor of Medicine and Associate Chief of the Section of Cardiovascular Medicine at Yale University School of Medicine, Investigator at the Center for Outcomes Research and Evaluation, and Medical Director for Value Innovation at the Yale New Haven Health System. Selected references: Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1) :S246–S260 Finerenone in Type 1 Diabetes and Chronic Kidney Disease. N Engl J Med 2026;394:947-957 Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229 Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446 Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121

GLPs are everywhere right now — but do you actually know what they are or what they do? In this episode I break down the reality of GLP-1, what it is, how it works, and how your body already has the natural ability to activate it through a fasting-focused lifestyle. Whether you're considering the shot or just curious about how it all works, this episode gives you the full picture so you can make the best decision for your health and future. _____ Are you ready for real, compassionate support on your fasting journey from someone who has actually lived it? I've shed over 200 pounds through fasting and have maintained it through some of the hardest seasons of life. If you're tired of doing this alone, you don't have to anymore. Come find your people: The Fasting Support Club _____ REFERENCES Habener, J.F. (2004). The discovery of glucagon-like peptide 1. ScienceDirect — Molecular and Cellular Endocrinology. Retrieved from sciencedirect.com Mass General Brigham Newsroom. (2025). Joel Habener receives Breakthrough Prize in Life Sciences for contributions to GLP-1 medications. Retrieved from massgeneralbrigham.org Journal of Clinical Investigation. (2024). Joel Habener, Svetlana Mojsov, and Lotte Bjerre Knudsen awarded Lasker Prize for pioneering work on GLP-1. Retrieved from jci.org Eng, J. (1992). Discovery of exendin-4 in Gila monster venom. VA Medical Center, Bronx, NY. Referenced in: PlexusDx. (2026). History of GLP-1 drugs: Complete timeline from exenatide to tirzepatide. Retrieved from plexusdx.com Fella Health. (2025). What is GLP-1 lizard venom: Gila monster discovery to diabetes drugs. Retrieved from fellahealth.com U.S. Food and Drug Administration. (2005). Approval of exenatide (Byetta) for type 2 diabetes. FDA Drug Approval Database. Acosta, A. & Ghusn, W. (2023). Semaglutide shown to be effective for weight loss in multicentre, one-year real-world study. European Congress on Obesity (ECO2023). Presented by Precision Medicine for Obesity Program, Mayo Clinic. Retrieved from eurekalert.org Mayo Clinic Press. (2026). Health benefits of semaglutide beyond weight loss. Retrieved from mcpress.mayoclinic.org National Institutes of Health / NCBI. (2024). Patient perceptions of Ozempic (semaglutide) for weight loss: Mixed methods analysis of online medication reviews. Retrieved from ncbi.nlm.nih.gov National Institutes of Health / NCBI. (2024). Evaluation of pre-treatment assessment of semaglutide users: Balancing the benefits of weight loss vs. potential health consequences. Retrieved from ncbi.nlm.nih.gov Fung, J. (2016). The Obesity Code: Unlocking the secrets of weight loss. Greystone Books. Fung, J. (2025). The Hunger Code: Resetting your body's fat thermostat in the age of ultra-processed food. Greystone Books.

Have you experienced False Hope Syndrome? Without telling you exactly what that is, I'm going to let you know chances are good that you have. I have certainly done so in more than one area of my life! False Hope Syndrome runs rampant in relation to weight loss. Listen in, learn exactly what it is and how to keep yourself safe from falling into the disappointment associated with False Hope Syndrome as you move forward in losing and maintaining weight loss.The Weight Loss Winformation Podcast gives you essential psychological information to help you lose weight and more importantly, to help keep you at a healthy weight for your body! No matter how you are working to lose weight and no matter how much weight you want to lose, Weight Loss Winformation will keep you moving in a positive direction. Let's get started because well… Why Weight? (get it? Pun intended… )?Resources:·      BariAfterare: www.bariaftercare.com·      Connie Stapleton PhD website: www.conniestapletonphd.com·      BariAftercare website: https://www.conniestapletonphd.com/bariaftercare·      BariAftercare Facebook page (for members only): https://www.facebook.com/groups/BariAftercare·      Kevin Stephens: Your Bariatric Buddy   https://www.facebook.com/groups/yourbariatricbuddy/people·      Instagram: @ (Caleshia Haynes)·      Instagram: @therealbariboss (Tabitha Johnson)·      Instagram @drsusanmitchell (Dr. Susan Mitchell)·      Instagram: @lauraleepreston (Laura Preston)·      ProCare Vitamins (10% off with code ConnieStapleton)·      Rob DiMedio: https://www.busybariatrics.com/·      Dr. Joan Brugman: drjbrugman@outlook.com·      Dr. Nestor de la Cruz-Munoz on Linked In: https://www.linkedin.com/in/drdelacruzmunoz/From: How Much Weight Will You Lose After Bariatric Surgery? Nestor de la Cruz-Munoz MD, FACS, DABOMJuly 12, 2026 The Evidence Is Clear — And It's Not What Most Patients Expecto    The AACE/TOS/ASMBS guidelines are explicit: Very few preoperative factors are sufficiently predictive to give a precise individual weight loss number.This means the honest answer is not a number — it's a range.The Real Weight Loss Ranges by ProcedureThe most reliable metric is total weight loss percentage (TWL) — not excess weight loss.Sleeve Gastrectomy (SG)·       23–25% TWL at 1 year·       17–19% TWL at 5 years·       PCORnet (65,000+ patients): 18.8% TWL at 5 yearsRoux‑en‑Y Gastric Bypass (RYGB)·       28–31% TWL at 1 year·       21–26% TWL at 5 years·       20–27% TWL at 10 years·       PCORnet: 25.5% TWL at 5 years·       SM‑BOSS RCT: 27.5% TWL at 10 yearsOne‑Anastomosis Gastric Bypass (OAGB)·       Highest early TWL·       Emerging evidence suggests greater long‑term durability than SG and RYGB·       Randomized TrialsBy‑Band‑Sleeve RCT (3‑year outcomes):·       RYGB: 26.8% TWL·       Sleeve: 19.4% TWL·       Band: 14.0% TWLWeight regain after cessation of medication for weight management: systematic review and meta-analysiso   West S, Scragg J, Aveyard P, Oke JL, Willis L, Haffner SJP, Knight H, Wang D, Morrow S, Heath L, Jebb SA, Koutoukidis DA. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026 Jan 7;392:e085304. doi: 10.1136/bmj-2025-085304. PMID: 41500720; PMCID: PMC12776922.o   https://pubmed.ncbi.nlm.nih.gov/41500720/·       The primary anti-obesity medications (AOMs) highlighted in this high-level study are newer incretin mimetics, specifically:o   Semaglutide (a GLP-1 receptor agonist)o   Tirzepatide (a GIP/GLP-1 receptor co-agonist)The Rebound Effect: High-Level EvidenceThis January 2026 systematic review and meta-analysis published in The BMJ synthesized data from 37 studies involving 9,341 participants, providing robust, high-level clinical evidence on what happens after stopping these medications:·       Rapid Return to Baseline: On average, patients return to their baseline weight within 1.7 years after stopping any weight management medication.·       Accelerated Regain for GLP-1/GIP Drugs: For those stopping semaglutide or tirzepatide, the rebound is even faster—returning to baseline weight in just 1.5 years.·       Faster than Behavioral Programs: The rate of weight regain after medication cessation is significantly faster than the regain observed after finishing behavioral weight management programs.·       Reversal of Health Benefits: Stopping these therapies also rapidly reverses their positive, beneficial effects on cardiometabolic markers.·       These findings emphasize that using these medications short-term without a more comprehensive, long-term approach to weight management leads to a rapid reversal of both weight loss and cardiometabolic improvements, and this is the real benefit we can offer to our patients: a long-term plan that can and should be updated on the course of their chronic disease and its natural course. Nothing in obesity treatment should be absolutely static.·      How to overcome past dieting failures. By Kristen A. Carter MSo   https://www.psychologytoday.com/us/blog/health-and-human-nature/202103/false-hope-syndrome-reveals-big-problem-dieting·      Getting Real: Warning Signs of False Hope Syndrome. by Dan J. Tomasulo PhD., TEP, MFA, MAPPo   https://www.psychologytoday.com/us/blog/the-healing-crowd/202209/getting-real-warning-signs-of-false-hope-syndrome·      Expected Weight Loss From Gastric Bypass – Calculatoro   https://www.obesitycoverage.com/weight-loss-surgeries/gastric-bypass/how-much-can-i-expect-to-lose·      Expected Weight Loss (after Sleeve)o   https://www.obesitycoverage.com/gastric-sleeve-reference-manual/

Two experts in obesity medicine discuss the latest advances in obesity care, including: Current data for incretin-based therapies Beyond the scale—individualizing OMM selection based on weight-related comorbidities and cardiometabolic risk Common contraindications and warnings associated with certain OMMs Shared decision-making strategies to inform treatment selection. [JF1]Added this to the episode notes to maybe help with the posttest  Presenters Amy Butts, PA-C, DFAAPA, BC-ADM, CDCES Endocrine Physician Associate WVU Medicine Wheeling Hospital Immediate Past President of American Society of Endocrine Physician Associates Wellsburg, West Virginia Nicholas Pennings, DO Professor of Family Medicine Campbell University School of Osteopathic Medicine Director of Clinical Education Obesity Medicine Association Buies Creek, North Carolina Link to full program:https://bit.ly/4v7eIY4 Get access to all of our new podcasts by subscribing to the Decera Clinical Education Multispecialty Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What if the peptide you just ordered online isn't wrong — it's just wrong for you? In Episode 2 of our peptides series, clinical pharmacist Dr. Melissa Jones takes us inside the actual decision-making process providers use to match a peptide to a patient, and why skipping that process is how people end up wasting money, or worse, hurting themselves. Host Jamie Preston and Dr. Jones dig into the real science: what a peptide is, how peptides signal the body, and why a healthy foundation — hormones and gut health — has to come before any peptide is even considered. From there, they cover the wide menu of options (tissue repair, skin and hair, sexual health, growth hormone support, metabolic health, sleep and stress) and what it actually means to “stack” or “cycle” peptides responsibly. In this episode, you'll hear: Why there isn't — and won't be — one peptide that does it all, and what that means for how providers build a plan How stacking and cycling actually work, and where cost becomes a real factor in the decision The difference between FDA-approved peptide uses (like Tesamorelin for visceral fat) and the anecdotal dosing happening across the wellness world The real danger in reconstituting and self-dosing peptides ordered online, explained in plain terms What responsible, supervised GLP-1 (Mounjaro, Ozempic, tirzepatide) therapy looks like — and what goes wrong with compounded, unregulated versions The specific list of patients who should avoid peptides or use extra caution, and why providers need to know it cold If you've ever wondered whether a peptide could actually help you — or wondered what your provider is really weighing before saying yes — this episode gives you the real answer, not the Instagram version. www.YourHealth.Org

This video reveals how your skin uses glutathione to defend itself, how Dr. Nayan Patel solved its delivery problem, and why his topical antioxidant serum was clinically shown to improve the appearance of fine lines, wrinkles, and skin tone in just 1 week.You'll also learn:The molecule (glutathione) behind clinically-backed wrinkle reduction in 7 daysWhy oxidative stress, not just low collagen, drives visible skin agingHow free radicals damage collagen, elastin, and skin toneWhy glutathione is the body's "master antioxidant" for skin protectionThe 4 barriers any skincare ingredient must survive to actually work (bioavailability)The delivery system breakthrough (RO-GSH) that finally makes topical glutathione effectiveHow to use the full glutathione skincare system (serum, copper peptides, vitamin C) for results in one weekTry Danger Creatine: https://dangercoffee.com/products/danger-creatineTry TrueDark glasses: https://truedark.comTry Danger Coffee: https://dangercoffee.com/discount/davetubeTry Suppgrade Labs: https://shopsuppgradelabs.com/Thank you to our sponsors!PredictiveMind™ | Get your Brain Pattern Mapping report at predictivemind.io/dave and use code DAVE for 10% off.Viome | Check it out at viome.com and use code 16DAVE for 16% off. It's time to stop guessing and start knowing your body.iRestore | Reverse hair loss at www.irestore.com/DAVE and get exclusive savings on the iRestore Elite, use code DAVETimestamps:00:00 - Intro00:19 - Anti-Aging Drug Screening01:43 - Protein Restriction & Aging03:36 - New Skin Injectable05:23 - Arts & Longevity07:30 - Biohacking Interventions Reviewed08:51 - Semaglutide & Aging Clocks09:29 - Closing TakeawaysConnect with Dave Asprey!Website: https://daveasprey.comTikTok: https://www.tiktok.com/@daveaspreyofficialInstagram: https://www.instagram.com/dave.asprey/Facebook: https://www.facebook.com/Daveaspreyofficial/X: https://x.com/daveaspreyYouTube: https://www.youtube.com/c/daveaspreybprThe Human Upgrade Podcast: https://www.instagram.com/TheHumanUpgradePodcast/ https://m.facebook.com/Thehumanupgrade/Dave Asprey's BEYOND Conference: https://beyondconference.com/Dave Asprey's New Book - Heavily Meditated: https://daveasprey.com/heavily-meditated/Dave's favorite supplements: https://www.shopsuppgradelabs.com/discount/DAVE15Upgrade Labs: https://upgradelabs.com40 Years of Zen: https://40yearsofzen.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Subtitle: A Nasal Spray Longevity Screen, Why Less Protein May Age You Better, Cadaver Skin Injectables, Art's Effect on Biological Age, and Which Anti-Aging Interventions Actually Move the Needle Nasal Spray Ingredient Emerges As Unexpected Longevity Candidate In Massive Drug Screen Researchers mapped 2,358 longevity-associated genes across the body's broader protein and signaling networks, then screened 6,442 approved drugs to see which ones nudged those aging pathways in a healthier direction. Oxymetazoline, the active ingredient in nasal sprays like Afrin, was among 21 standout candidates, with a predicted pathway running through the ACKR3 receptor and connecting to major aging proteins including NF-kB, TP53, and AKT1. Host Dave Asprey explains why this computational screen is a promising research lead rather than a protocol, and why chronic use of a vasoconstricting nasal spray carries real risks regardless of what a network analysis suggests. Sources: https://www.inc.com/lucia-auerbach/scientists-screened-6442-drugs-for-longevity-common-nasal-spray-emerged-as-a-surprising-candidate/91381000 https://www.sciencealert.com/medications-already-in-pharmacies-may-slow-aging-and-scientists-are-narrowing-them-down https://pmc.ncbi.nlm.nih.gov/articles/PMC12425021/ ~~ New Review Of 350+ Studies Asks Whether Less Protein Means Longer Life A review spanning more than 350 studies found that protein restriction consistently extended lifespan and improved metabolic health across mice, rats, flies, and fish, with smaller human studies showing improvements in body fat and fasting glucose even when total calorie intake rose. Researchers point to FGF21, a liver hormone that rises under protein or amino acid scarcity and boosts energy expenditure and glucose regulation, as a key mechanism. Host Dave Asprey breaks down why blanket protein advice fails older adults preserving muscle and highly active people just as badly as it fails everyone else, and why matching intake to actual biology beats maximizing protein at every meal. Sources: https://www.medicalnewstoday.com/articles/why-reducing-protein-intake-could-promote-healthy-aging-new-research https://time.com/article/2026/08/03/eat-less-protein-age-better-live-longer/ https://www.sciencedaily.com/releases/2026/08/260801042811.htm https://www.cell.com/cell-reports-blue/fulltext/S2949-8821(26)00079-9 https://pmc.ncbi.nlm.nih.gov/articles/PMC8991228/ https://www.eurekalert.org/news-releases/1137190 ~~ Processed Cadaver Skin Injectable Enters The Anti-Aging Market As Elravie Re2O A new injectable called Elravie Re2O, short for "return to your 20s," is made from donated human skin processed to remove living cells and most genetic material, leaving a collagen-rich extracellular matrix that gets injected into the face and neck as a biological scaffold rather than a simple filler. Human-derived tissue matrices already have a track record in burn and wound care, but this specific product is not yet FDA-approved and lacks comparative trial data against existing fillers. Host Dave Asprey separates legitimate regenerative medicine from a novel cosmetic product still waiting on long-term safety and consistency data. Sources: https://nypost.com/2026/07/21/health/the-hottest-new-anti-aging-treatment-cadaver-skin/ https://www.newsobserver.com/living/article316698211.html https://www.miamiherald.com/living/article316698295.html https://pmc.ncbi.nlm.nih.gov/articles/PMC12985180/ https://laboderm-skin.com/elravie-re2o-application/ ~~ UCL Study Finds Weekly Arts Engagement Tracks With Slower Epigenetic Aging A University College London study of more than 3,500 adults found that people who engaged weekly with arts and culture, including painting, music, museums, and theater, showed a roughly four percent slower pace of aging on the DunedinPACE clock and appeared about one biological year younger on PhenoAge, with the effect holding after adjusting for income, education, smoking, and physical activity. Benefits appeared whether people were actively creating art or simply attending performances and exhibits. Host Dave Asprey argues this expands what counts as a health input beyond molecules and devices, since novelty, meaning, and social connection influence the nervous system too. Sources: https://www.npr.org/2026/05/12/nx-s1-5818172/study-arts-slow-biological-aging https://www.news-medical.net/news/20260511/Regular-arts-engagement-may-help-slow-biological-aging-process.aspx https://studyfinds.com/arts-culture-may-slow-aging/ ~~ Review Of 41 Human Studies Ranks Which Interventions Actually Shift Epigenetic Clocks A review of 41 human studies testing interventions against newer-generation epigenetic clocks found favorable changes for exercise, caloric restriction, omega-3s, plant-rich diets, multivitamins, semaglutide, pitavastatin, and ketamine, while nicotinamide riboside, rapamycin, and senolytics showed no detected clock improvement in the studies reviewed. Semaglutide produced the strongest single result, slowing DunedinPACE by about nine percent in a trial of adults with HIV-associated fat redistribution, though a separate fatty liver study produced mixed outcomes. Host Dave Asprey explains why a strong mechanistic story does not guarantee a moved biomarker, and why clinical outcomes, functional measures, and safety data all matter alongside any single clock reading. Sources: https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2026.1836446/full https://pubmed.ncbi.nlm.nih.gov/42294499/ https://www.news-medical.net/news/20260616/Semaglutide-omega-3s-and-diet-shift-epigenetic-aging-clocks-in-human-studies.aspx https://www.nature.com/articles/s41514-026-00383-9 https://pmc.ncbi.nlm.nih.gov/articles/PMC12338914/ https://medicalxpress.com/news/2026-06-popular-glp-drug-biological-aging.html https://www.creativebiomart.net/blog/semaglutide-may-slow-epigenetic-aging-in-humans https://www.aging-us.com/article/202913/text https://superpower.com/guides/can-you-reverse-epigenetic-age https://www.nature.com/articles/d41586-026-01836-7 https://www.businessinsider.com/first-ever-reverse-aging-drug-was-just-injected-into-a-human-2026-6 ~~ This episode is designed for biohackers, longevity enthusiasts, and high-performance listeners who want mechanism-level insights into a computational drug-repurposing screen, the case for eating less protein, a new regenerative injectable made from human tissue, the biological effect of creative engagement, and a data-driven ranking of which longevity interventions actually move epigenetic clocks. Host Dave Asprey connects computational biology, nutrition science, regenerative medicine, and biomarker research into practical frameworks for evaluating what belongs in a real longevity protocol versus what belongs on a watch list. New episodes every Tuesday, Thursday, Friday, and Sunday. Keywords: oxymetazoline longevity, drug repurposing screen aging, ACKR3 receptor aging pathway, protein restriction longevity, FGF21 hormone aging, low protein diet healthspan, cadaver skin injectable, Elravie Re2O, extracellular matrix regenerative medicine, anti-aging injectable 2026, arts engagement biological age, DunedinPACE epigenetic clock, PhenoAge biological age, epigenetic clock interventions, semaglutide epigenetic aging, rapamycin epigenetic clock, senolytics human trials, biological age testing, biohacking news 2026, Dave Asprey, The Human Upgrade Thank you to our sponsors! - KILLSwitch | If you're ready for the best sleep of your life, order now at https://www.switchsupplements.com/and use code DAVE for 20% off - Beyond Wonderland Conference | Oct 13 - 14, 2026. Get your ticket now at wonderlandconference.com. - iRestore | Reverse hair loss at www.irestore.com/DAVE and get exclusive savings on the iRestore Elite, use code DAVE Resources: • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Get My 2026 Biohacking Trends Report: https://daveasprey.com/2026-biohacking-trends-report/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Intro 00:19 – Anti-Aging Drug Screening 01:43 – Protein Restriction & Aging 03:36 – New Skin Injectable 05:23 – Arts & Longevity 07:30 – Biohacking Interventions Reviewed 08:51 – Semaglutide & Aging Clocks 09:29 – Closing Thoughts See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Could you please comment on the new study that finds protein restriction could slow aging?Considerations for protein intake across the lifespanMy bone mineral density has improved with strontium. Should I stop taking it?  What about vitamin K2?

Novo Nordisk has spent years warning patients, regulators, lawmakers, and courts about the risks of synthetic semaglutide. Now, as patents begin to expire and China's pharmaceutical industry becomes increasingly important, Novo may be staring at a very uncomfortable question: what happens if synthetic semaglutide suddenly makes sense when Novo is the one making it?In this week's episode of The Weekly Dose, I dig into Novo's long-running recombinant-versus-synthetic semaglutide argument, the lawsuits and FDA petitions built around it, and a clip from more than 16 months ago showing that we were covering this exact issue long before it became part of the mainstream conversation. Novo Warned Us About Synthetic Semaglutide_ Now This_.txtWe also break down Pfizer's decision to kill two clinical-stage obesity drugs, including an oral GLP-1 acquired through its $10 billion Metsera deal, the strange science behind GIP receptor antagonism, and why Pfizer's remaining obesity pipeline still deserves attention. Plus, Wall Street is looking at Eli Lilly's obesity-fueled rally and asking just how big this market can get.In this episode:00:00 Novo's synthetic semaglutide problem02:00 VoaFit sponsor message03:30 The 16-month-old On The Pen receipt05:00 Recombinant vs. synthetic semaglutide07:00 Novo's FDA, legal, and political strategy09:00 Pfizer kills two obesity drugs11:00 What happened to Metsera's oral pipeline?13:00 The GIP agonist vs. antagonist paradox15:00 Why China matters to Pfizer and Novo17:00 Could Novo eventually make synthetic semaglutide?18:30 What comes next for Lilly, Novo, and PfizerThe big question: If Novo Nordisk eventually launches its own synthetically manufactured semaglutide, does that change how you view the arguments it has made against compounded semaglutide over the last several years?Comment below. I want to know where you land.More obesity medicine news and analysis: OnThePen.comAll my links, socials, and resources: linktr.ee/manonthemounjaroThis episode is sponsored by VoaFit. Learn more at voafit.com/otp.#GLP1 #Semaglutide #Ozempic #Wegovy #NovoNordisk #CompoundedSemaglutide #ObesityMedicine #Pfizer #EliLilly #Mounjaro #Zepbound #Metsera

You've seen the ads. You've heard the buzz. But do you actually know what peptides are — or what they're doing inside your body? In this first episode of a three-part series, Jamie Preston sits down with Dr. Melissa Jones, a 25-year clinical pharmacist and VP at Your Health, to lay the foundation every patient and provider needs before entering the peptide conversation. Dr. Jones brings rare credibility to this space — she didn't come in as a believer, she came in as a scientist who was challenged to learn, and what she found changed how she practices. What you'll hear in this episode: Why insulin is a peptide — and why that means peptides have been in your medicine cabinet for years How BPC 157 and TB 500 work together to signal the body to heal — and the real patient stories behind that science Why GLP-1 medications like Mounjaro and Ozempic are peptides, and how they actually produce weight loss The difference between peptides and steroids (hint: one sends signals, one messes with your hormones) Why "research use only" labels are a red flag — and why compounding pharmacies matter more than you think What providers need to start asking patients right now Whether you're a patient who's been curious or a provider who's been hesitant, this episode gives you the grounded, evidence-informed starting point you've been looking for. Part two goes even deeper — but this is where it begins. www.YourHealth.Org

What if the real question isn't "Which peptide should I take?" but "Do I need one at all?"Peptides like Ozempic (GLP-1 medications), BPC-157, MOTS-c, CJC-1295, and other bioactive peptides have exploded in popularity for weight loss, fat burning, muscle recovery, longevity, metabolism, and anti-aging. But are they truly the best solution—or could they be masking the underlying problem?In this episode of Accelerated Health with Sara Banta, I break down the science behind today's most talked-about peptides, who may actually benefit from them, their potential risks and side effects, and why supporting your body's natural healing pathways may be just as important.If you're considering peptides—or you're simply curious whether these trending treatments are worth the hype—this is an episode you won't want to miss.Supplements Featured In This Episode:• Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement • Accelerated Fast® https://www.acceleratedhealthproducts.com/products/accelerated-fast-supplement • Accelerated Ancient Salt® https://www.acceleratedhealthproducts.com/products/accelerated-ancient-salt-4-oz• Accelerated Liver Care® https://www.acceleratedhealthproducts.com/products/accelerated-liver-care• Accelerated Methylene Blue® https://www.acceleratedhealthproducts.com/products/accelerated-methylene-blue-supplementNot sure what food to eat and avoid? This guide is for you.⬇️

You might think the win on a GLP-1 like Ozempic or Mounjaro is the number dropping on your scale, but I need you to ask a better question, not how much you're losing, but what kind. In some studies, 40 to 60% of the weight people lost on these drugs came from lean muscle, not fat, and that's a metabolic loss that costs you your strength and your ability to keep the weight off. These are the most powerful fat-loss tools we've ever had, but a tool without a protocol is just potential. Hit your protein and lift, or you're trading muscle for a number you'll spend years trying to earn back. CLICK HERE TO BECOME GARYS VIP!: https://bit.ly/4ai0Xwg Thank you to our partners A-GAME: “ULTIMATE15” FOR 15% OFF: http://bit.ly/4kek1ij AION: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4h6KHAD AIRES: "ULTIMATE20 " FOR 20% OFF: https://bit.ly/4a3Duze BAJA GOLD: "ULTIMATE10" FOR 10% OFF: https://bit.ly/3WSBqUa BODYHEALTH: “ULTIMATE20” FOR 20% OFF: http://bit.ly/4e5IjsV COLD LIFE: THE ULTIMATE HUMAN PLUNGE: https://bit.ly/4eULUKpCYMBIOTIKA: "BRECKACYM30" FOR 30% OFF: https://bit.ly/4tjyluP GENETIC METHYLATION TEST (UK ONLY): https://bit.ly/48QJJrk GENETIC TEST (USA ONLY): ⁠https://bit.ly/3Yg1Uk9 GOPUFF: GET YOUR FAVORITE SNACK!: https://bit.ly/4obIFDC H2TABS: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4hMNdgg HEALF: 10% OFF YOUR ORDER: https://bit.ly/41HJg6S PEPTUAL: “TUH10” FOR 10% OFF: https://bit.ly/4mKxgcn SNOOZE: LET'S GET TO SLEEP!: https://bit.ly/4pt1T6V WHOOP: JOIN & GET 1 FREE MONTH!: https://bit.ly/3VQ0nzW Watch  the “Ultimate Human Podcast” every Tuesday & Thursday at 9AM EST: YouTube: https://bit.ly/3RPQYX8 Podcasts: https://bit.ly/3RQftU0 Connect with Gary Brecka Instagram: https://bit.ly/3RPpnFs TikTok: https://bit.ly/4coJ8fo X: https://bit.ly/3Opc8tf Facebook: https://bit.ly/464VA1H LinkedIn: https://bit.ly/4hH7Ri2 Website: https://bit.ly/4eLDbdU Merch: https://bit.ly/4aBpOM1 Newsletter: https://bit.ly/47ejrws Ask Gary: https://bit.ly/3PEAJuG Timestamps 00:00 - Intro of Show 00:22 - Weight loss vs fat loss 00:38 - What GLP-1 does in the body 01:02 - Semaglutide: the first generation 01:28 - Tirzepatide and the dual agonist 01:45 - Retatrutide and 24.2% body weight loss 02:20 - Why each added receptor works 02:38 - The hidden cost: protecting lean muscle 03:05 - 60% of weight loss from muscle 03:35 - The two-part fix: protein and training 04:05 - Protein targets and leucine-rich sources 04:30 - Resistance training and compound lifts 05:00 - Use the medication, do the work Disclaimer: This podcast is for informational purposes only and does not provide medical advice. It is not intended for diagnosing or treating any health condition. Always consult a licensed healthcare professional before making health or wellness decisions.  Gary Brecka is the owner of Ultimate Human, LLC which operates The Ultimate Human podcast and promotes certain third-party products used by Gary Brecka in his personal health and wellness protocols and daily life and for which Ultimate Human LLC and / or Gary Brecka directly or indirectly holds an economic interest or receives compensation.  Accordingly, statements made by Gary Brecka and others (including on The Ultimate Human podcast) may be considered promotional in nature. Learn more about your ad choices. Visit megaphone.fm/adchoices

CardioNerds (Drs. Apoorva Gangavelli, Jenna Skowronski, and Hannah Every) discuss the continuum of prevention and heart failure with Drs. Anu Lala and Martha Gulati. Grounded in a clinical case of a 55-year-old woman with uncontrolled hypertension, type 2 diabetes, and obesity who is on the trajectory toward heart failure, this episode unpacks a paradigm-shifting framework from a joint HFSA/ASPC Scientific Statement. The discussion explores how prevention should not be siloed from heart failure management but rather integrated across a patient’s lifespan—from primary prevention in at-risk individuals, to secondary prevention in those with established heart failure, to tertiary prevention in patients with advanced therapies such as LVADs and heart transplantation. The experts highlight the importance of aggressive risk factor management, biomarker-guided screening, the AHA’s Life’s Essential 8, and the need for multidisciplinary collaboration and systems-level change to shift heart failure care from reactive to proactive. Audio editing for this episode was performed by CardioNerds Intern, Dr. Julia Marques Fernandes. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Prevention PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Systemic inflammatory diseases are associated with an elevated CVD risk that has significant implications for early detection, risk Heart failure prevention is a continuum, not a checkpoint. Prevention applies at every stage—from at-risk (Stage A) through advanced/post-transplant care—and every clinical encounter is an opportunity to intervene. The AHA’s Life’s Essential 8 (diet, physical activity, nicotine exposure, sleep, BMI, blood lipids, blood glucose, blood pressure) forms the foundation at every stage. Hypertension carries the highest population-attributable risk for heart failure of any modifiable risk factor. In the Framingham Heart Study, 91% of patients with newly diagnosed HF had pre-existing hypertension. The SPRINT trial demonstrated a 38% reduction in HF incidence with intensive blood pressure targets (30 ng/L or NT-proBNP >125 ng/L) identify individuals at heightened risk for progression to symptomatic HF. The ACC/AHA/HFSA guidelines give a Class IIa recommendation for natriuretic peptide screening in at-risk patients. Urine albumin-to-creatinine ratio (UACR) is an underutilized screening tool that provides additional insight into CKM risk. The heart failure label does not close the prevention window—it accentuates it. Secondary prevention through GDMT optimization (quadruple therapy in HFrEF) and continued risk factor management remains critical. Tertiary prevention extends to post-LVAD and post-transplant patients, where hypertension, diabetes, obesity, and CKD management remain essential to long-term outcomes. Show notes For a comprehensive review, please review the full HFSA/ASPC Joint Scientific Statement: Lala A, Beavers C, Blumer V, et al. The Continuum of Prevention and Heart Failure in Cardiovascular Medicine. J Card Fail. 2026;32:75-105. doi:10.1016/j.cardfail.2025.06.013 1. What is the “continuum of prevention” framework, and how does it differ from traditional approaches to heart failure prevention? Historically, prevention and heart failure management have been treated as separate disciplines—primary prevention handled by preventive cardiologists and treatment managed by heart failure specialists. This joint HFSA/ASPC Scientific Statement reframes prevention as a dynamic, continuous process that spans a patient’s entire lifespan, regardless of HF stage or ejection fraction. The framework maps onto the ACC/AHA HF staging system: Primary prevention targets Stage A (“at risk”) and Stage B (“pre-HF”) patients to reduce the burden of incident HF. Secondary prevention targets Stage C (symptomatic) and Stage D (advanced) patients to reduce the impact of established HF through GDMT optimization and ongoing risk factor management. Tertiary prevention encompasses risk factor management in patients with LVADs or heart transplants—populations where hypertension, diabetes, and obesity still drive outcomes. The Central Figure of the statement illustrates that Life’s Essential 8 (blood pressure and lipid control, diabetes management, exercise, sleep, smoking cessation, weight management, and diet/nutrition counseling) forms the foundation at every stage, with pharmacologic and device-based therapies layered on top as disease progresses (Figure) 2. How do traditional risk factors drive heart failure, and what should clinicians prioritize? Hypertension carries the greatest population-attributable risk for HF. In the Framingham Heart Study (N=5,143), HTN was associated with a 2- to 3-fold increased risk of HF, with a population-attributable risk of 39% in men and 59% in women. The SPRINT trial showed a 38% reduction in HF incidence and 25% reduction in the primary composite outcome with intensive BP targets (30 ng/L or NT-proBNP >125 ng/L) are associated with heightened risk for progression to symptomatic HF. In the ARIC study, incorporating NT-proBNP reclassified 20% of older adults without HF into Stage B. Factors that affect interpretation include age, sex, obesity (lower values), and CKD (higher values). High-sensitivity cardiac troponin (hs-cTn): Concentrations above the 99th percentile are now included in the definition of Stage B HF. Troponin testing may complement natriuretic peptides, particularly when BNP/NT-proBNP values are ambiguous. Risk scores: The PCP-HF equation predicts 10-year HF risk using traditional risk factors plus QRS duration. The AHA PREVENT score incorporates HF risk calculation and includes markers of kidney function (albuminuria, eGFR), though it may underestimate risk in men and Black adults. The CKM syndrome staging framework (Stages 0–4) provides a holistic approach to assessing systemic cardiovascular-kidney-metabolic risk. 4. What are the key nontraditional risk factors and cross-cutting themes in heart failure prevention? Genetics: Pathogenic cardiomyopathy variants exist in ~1 in 200 individuals in the general population. The HFSA and ACMG recommend cascade testing to identify at-risk family members. Polygenic risk scores for dilated cardiomyopathy show a 3.8-fold risk for DCM in the top 10th percentile compared with the median. Sex-specific considerations: Women have 2.8 times the odds of developing HFpEF, while men have similarly increased odds of HFrEF. A complete obstetric/gynecologic history is essential—preeclampsia is associated with a 4-fold increased risk of HF. Peripartum cardiomyopathy requires intentional screening in high-risk populations. Cardiotoxic exposures: Clinicians should be aware of medications that cause direct myocardial toxicity (e.g., anthracyclines, trastuzumab, tyrosine kinase inhibitors). A team-based approach with pharmacists can help optimize medication selection and risk factor modification. Social determinants of health: Environmental exposures (air pollution, arsenic, lead, cadmium), food insecurity, financial instability, and limited healthcare access contribute to HF risk and progression. Equity-focused, risk-based prevention strategies are needed. Psychological health: Depression is common in HF and independently associated with worse outcomes. Screening with brief questionnaires (e.g., PHQ-2) is recommended. Meditation, spirituality, and holistic wellness approaches remain underutilized. 5. What systems-level and policy changes are needed to move the needle on heart failure prevention? Multidisciplinary HF prevention clinics that bring together preventive cardiologists, HF specialists, endocrinologists, nephrologists, dietitians, pharmacists, exercise physiologists, and genetic counselors are advocated by the statement. EHR-embedded risk stratification could proactively flag patients on a trajectory toward HF—analogous to sepsis alerts or fall risk flags—enabling earlier intervention, particularly for patients who may not reach a cardiologist. Cardiac rehabilitation remains underutilized, particularly in HFrEF (Class 2b recommendation) and HFpEF (not yet covered by Medicare). The HF-ACTION trial showed quality-of-life benefits, and the REHAB-HF trial showed particular benefit in older patients with HFpEF. Policy priorities include expanding insurance coverage for preventive screening and novel therapies (SGLT2i, GLP-1 RAs, nsMRAs), reducing clinical inertia through team-based care models with closer follow-up intervals, and ensuring equitable access to evidence-based therapies across diverse populations. Digital health and AI hold promise for personalized risk prediction, remote monitoring (e.g., wearable devices, implantable PA pressure monitors), and virtual cardiac rehabilitation to overcome access barriers. Figure  Lala A, Beavers C, Blumer V, et al. The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology. J Card Fail. 2026;32(1):75-105. doi:10.1016/j.cardfail.2025.06.013) References Key references are bolded. Lala A, Beavers C, Blumer V, et al. The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology. J Card Fail. 2026;32(1):75-105. doi:10.1016/j.cardfail.2025.06.013 Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063 Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life’s Essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health: a presidential advisory from the American Heart Association. Circulation. 2022;146(5):e18-e43. doi:10.1161/CIR.0000000000001078 SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116. doi:10.1056/NEJMoa1511939 Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557-1562. doi:10.1001/jama.1996.03530440037034 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997. doi:10.1001/jama.288.23.2981 Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-153. doi:10.1056/NEJM200001203420301 Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720 Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089-1098. doi:10.1056/NEJMoa2206286 Filippatos G, Anker SD, Agarwal R, et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation. 2022;145(6):437-447. doi:10.1161/CIRCULATIONAHA.121.057983 Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475-1485. doi:10.1056/NEJMoa2407107 Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563 Deanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10454):773-786. doi:10.1016/S0140-6736(24)01498-3  Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963 Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation. 2023;148(20):1636-1664. doi:10.1161/CIR.0000000000001175 Khan SS, Matsushita K, Sang Y, et al. Development and validation of the American Heart Association’s PREVENT equations. Circulation. 2024;149(6):430-449. doi:10.1161/CIRCULATIONAHA.123.067626 Khan SS, Ning H, Shah SJ, et al. 10-year risk equations for incident heart failure in the general population. J Am Coll Cardiol. 2019;73(19):2388-2397. doi:10.1016/j.jacc.2019.02.057 Bozkurt B, Fonarow GC, Goldberg LR, et al. Cardiac rehabilitation for patients with heart failure: JACC expert panel. J Am Coll Cardiol. 2021;77(11):1454-1469. doi:10.1016/j.jacc.2021.01.030 Packer M. Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity. Circulation. 2018;137(15):1614-1631. doi:10.1161/CIRCULATIONAHA.117.032474 Lala A, Tayal U, Hamo CE, et al. Sex differences in heart failure. J Card Fail. 2022;28(3):477-498. doi:10.1016/j.cardfail.2021.10.006 Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure. Eur J Heart Fail. 2021;23(3):352-380. doi:10.1002/ejhf.2115 Hershberger RE, Givertz MM, Ho CY, et al. Genetic evaluation of cardiomyopathy—a Heart Failure Society of America practice guideline. J Card Fail. 2018;24(5):281-302. doi:10.1016/j.cardfail.2018.03.004 Levine GN, Cohen BE, Commodore-Mensah Y, et al. Psychological health, well-being, and the mind-heart-body connection: a scientific statement from the American Heart Association. Circulation. 2021;143(10):e763-e783. doi:10.1161/CIR.0000000000000947 Ezekowitz JA, Colin-Ramirez E, Ross H, et al. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. Lancet. 2022;399(10333):1391-1400. doi:10.1016/S0140-6736(22)00369-5

¿Has escuchado maravillas sobre medicamentos como Ozempic, Wegovy o Mounjaro, pero nadie te habla de las constantes náuseas y el malestar estomacal? La realidad clínica es que una gran parte de los pacientes abandonan estos tratamientos para la obesidad simplemente porque los efectos secundarios arruinan su calidad de vida. Pero la ciencia médica está a punto de dar un salto monumental. En este episodio, descubriremos a la AMILINA, una hormona producida por tu páncreas que está demostrando resultados asombrosos en ensayos clínicos: pérdida de peso significativa sin los severos vómitos ni malestares intestinales de los fármacos actuales. En este episodio aprenderás: → Cómo tu páncreas libera dos hormonas cada vez que comes. → Cómo la amilina bloquea el freno metabólico que hace que recuperes el peso perdido. → Cómo dos equipos de investigadores resolvieron el mismo problema químico de formas distintas. → Cómo la combinación CagriSema alcanza una reducción significativa del peso corporal. → Por qué la amilina resensibiliza tu cerebro a la leptina, algo que la semaglutida no logra.   Mi nombre es Dr. Mauricio González, médico internista y especialista en endocrinología en formación. Aquí comparto información basada en evidencia para que tomes decisiones de salud sin mitos ni marketing engañoso. Suscríbete a mi boletín informativo en: www.drmauriciogonzalez.com/   ⚠️ Este podcast tiene fines exclusivamente educativos e informativos y no constituye asesoramiento médico, diagnóstico ni tratamiento personalizado. Los medicamentos que se discuten en este episodio se encuentran en fase de investigación y no cuentan con aprobación de la FDA. Consulta siempre a tu médico o a un profesional de la salud calificado antes de cambiar tu régimen de tratamiento.   ¡Sigamos la conversación en redes sociales! Instagram

Why Women Need 7-20 Minutes to "Warm Up", And Why That's Normal | FT: NikkiCONNECT WITH CHARLENEOn Instagram @mscharlenebyars([https://www.instagram.com/mscharlenebyars]On YouTube @chosentraining(https://www.youtube.com/@lovestorieswithcharlenebyars))Work with me HERE([https://charlenebyars.com/](https://charlenebyars.com/))In this candid conversation, desire coach and sexuality educator Nikki joins the podcast to break down the anatomy and psychology of female arousal, information most women were never taught growing up.The episode covers the truth about clitoral anatomy (including why the "G-spot" debate is more nuanced than most people realize), the concept of "tenting" and why arousal needs time to build before penetration, and why the widely cited 7-20 minute warm-up window varies so much from person to person.TIMESTAMP:00:00 — Intro: Meet Nikki, Desire Coach & "Sextainer"02:15 — Nikki's Story: From Closed Off to Owning Her Pleasure04:30 — The 73-Year-Old Client Who Changed Everything07:00 — Why We Never Learned About Female Anatomy09:45 — Clitoris vs. G-Spot: The Real Statistics Explained13:00 — What "Tenting" Means & Why It Matters16:30 — How Arousal Physically Changes the Body19:00 — Why 7-20 Minutes to "Warm Up" Is Normal21:15 — Responsive vs. Spontaneous Desire23:00 — Homework: The Memory Exercise for Couples25:30 — How Pregnancy, Perimenopause & Menopause Change Desire28:00 — Medications That Affect Libido (Antidepressants, Semaglutide, Antihistamines)30:15 — Sexual Trauma & When to Seek Additional Support32:00 — Why Desire Changes as Women Age34:00 — Pillar #1: Agency — Reclaiming Choice37:00 — Pillar #2: Context — Setting the Right Environment40:30 — Pillar #3: Permission — Affirmations for Pleasure43:00 — Pillar #4: Sensation — Blood Flow, Hormones & Vasodilators47:30 — Testing Hormones the Right Way (Optimal vs. "Normal")50:00 — Pillar #5: Energy — Why Timing of Day Matters53:00 — The "2 PM vs 8 PM" Concept & App-Controlled Toys56:00 — Pillar #6: Mindset — Getting Out of Multitasking Mode59:00 — Why Desire Doesn't Have to Come First1:01:30 — Understanding Sexless Marriages & How Habits Form1:02:00 — The Importance of Non-Sexual Touch1:03:00 — Why Orgasms Matter for Mental & Physical Health1:04:00 — A Word on Men's Sexual Health1:06:00 — Lubricant 101: What to Look For & Why It Matters1:08:00 — Teaching Daughters About Their Bodies1:0900 — Where to Find Nikki + Free Resources1:10:00 — Closing Thoughts: "Happy Humping"The conversation also explores responsive versus spontaneous desire, how major life changes, postpartum, perimenopause, medication side effects, and past sexual trauma, can shift how the body experiences pleasure, and practical communication exercises couples can use to reconnect.Nikki introduces her "6 Pillars of Playfulness" framework (agency, context, permission, sensation, energy, and mindset) as a roadmap for women who feel like their desire has faded in long-term relationships, along with simple, low-pressure homework couples can try together.This is an educational, relationship-focused conversation aimed at demystifying female sexuality, encouraging open communication between partners, and helping women reconnect with pleasure without shame.

As current understandings of obesity (ie, a chronic disease requiring long-term management) are adopted across the world, screening and treatment can no longer follow a one-size-fits-all approach. Listen in as 3 global experts in obesity medicine highlight the emerging evidence from recent conferences that are changing real-world practice today. Learn how the latest findings apply to specific patient populations across the United States, Europe, and Asia as well as why healthcare professionals should individualize treatment based on patient preferences and relevant risk factors. Presenters: Stephano Del Prato, MD Professor Emeritus of Endocrinology University of Pisa Pisa, Italy Soo Lim, MD, PhD Professor of Medicine Department of Internal Medicine Seoul National University College of Medicine and Seoul National University Bundang Hospital Seoul, South Korea Donna H. Ryan, MD Professor Emerita Pennington Biomedical Research Center Louisiana State University New Orleans, Louisiana Link to full program:https://bit.ly/4pwFhEo Get access to all of our new podcasts by subscribing to the Decera Clinical Education Multispecialty Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A Note from James:I'm doing a big experiment in my life.I recently started taking a GLP-1—tirzepatide, one of the so-called weight-loss drugs. But I didn't start taking it specifically for weight loss. I had some blood work done for the first time in a long time, and there was a small indication that I might be pre-diabetic. My doctor suggested trying tirzepatide, and I wanted to understand what I was getting into.The first person I wanted to talk to was Charles Duhigg, author of The Power of Habit and Supercommunicators. Charles has been taking a GLP-1 for about two years, and he says it has changed his life. He has lost around 45 pounds, but what interested me most was not just the weight loss. It was the habit change.Charles explains that GLP-1s can quiet what people now call “food noise”—the constant background pull toward eating even when you are not actually hungry. When that noise quiets down, something interesting happens: you get a window where your old habits become more malleable.That is the key idea of this conversation. The drug may help you eat less, but the bigger opportunity is that it gives you a chance to build new routines around food, exercise, alcohol, sleep, and identity. And if you build those habits while the window is open, those habits may continue even after you stop taking the medication.We talk about food noise, cravings, the habit loop, keystone habits, stated versus revealed preferences, placebo effects, alcohol, sleep, exercise, blood sugar, identity, and whether GLP-1s are a lifelong drug or a tool for changing who you become.Episode Description:James is at the beginning of a GLP-1 experiment. Charles Duhigg is two years in.In this conversation, Charles explains what he has learned from taking tirzepatide and from studying GLP-1s through the lens of habit formation. He describes the first phase of public understanding around these medications as weight loss. Phase two, he argues, is about behavior change.The central concept is “food noise.” Charles describes it as the background craving that turns a basket of fries into an almost automatic behavior. You may not even notice the noise until it goes away. Once it quiets, the cue that normally triggers the habit loop weakens. That creates a temporary window where new habits can be built.James and Charles use the GLP-1 experience to revisit the basic habit loop: cue, routine, reward. They talk about why habits feel automatic, why willpower is often the wrong tool, and why successful behavior change depends on identifying the cue and replacing the routine while still satisfying the underlying reward.Charles also introduces the idea of GLP-1s as a catalyst for keystone habits. Eating less can make exercise easier. Drinking less can improve sleep. Better sleep can improve focus. Focus can improve work. One changed habit can set off a chain reaction.The conversation then becomes more philosophical: Who are we if one part of the brain says “I want to be healthy,” while another part of the brain keeps revealing different preferences through action? Charles explains the difference between stated preferences and revealed preferences, and how repeated behavior can shift identity.This is not a conversation about taking GLP-1s casually. It is a conversation about using a medical intervention deliberately, under appropriate medical guidance, as a chance to change the patterns that shape daily life.Editorial Note:This episode discusses prescription medications, including tirzepatide and semaglutide, as well as personal experiences with GLP-1 drugs. It should not be treated as medical advice.GLP-1 medications can have side effects and risks, including gastrointestinal symptoms, dosing concerns, and contraindications for some patients. They should be used only under the supervision of a qualified medical professional. Any decision to start, stop, adjust, or combine medications should be made with a clinician.James and Charles also discuss personal experience, habit change, appetite, alcohol cravings, and identity. Individual responses to these medications vary.What You'll Learn:Why Charles believes GLP-1s are entering “phase two”: not just weight loss, but habit change.What “food noise” feels like—and why people often do not notice it until it disappears.How GLP-1s may create a temporary “habit window” where old routines become easier to change.Why the habit loop—cue, routine, reward—matters when trying to change eating behavior.Why people often regain weight after stopping GLP-1s if they have not built new habits.How keystone habits can create a chain reaction across food, exercise, alcohol, sleep, and focus.Why micro habits may work better than a full lifestyle overhaul.How stated preferences and revealed preferences shape identity.Why eating less can make exercise easier, and why exercise can reinforce healthier choices.Why tracking behavior may be essential while taking a GLP-1.How placebo, alter egos, and rituals may influence identity and performance.Why the goal is not just losing weight, but becoming the kind of person whose habits support health.Timestamped Chapters:[03:36] James Begins His GLP-1 ExperimentJames explains his early experience, including confusion between medication side effects and a bout of COVID.[04:16] Charles's Two-Year ExperienceCharles describes taking tirzepatide, losing roughly 45 pounds, and why the biggest changes came months into the process.[05:38] Phase One vs. Phase Two of GLP-1sPhase one was about appetite and weight loss. Phase two, Charles argues, is about habits that can last.[06:42] The Habit WindowHow GLP-1s can quiet food noise and create a period where eating habits become more malleable.[07:21] COVID, Side Effects, and Early SignalsJames explains why his first few weeks were hard to interpret and why he is still figuring out what the medication is doing.[09:00] What Food Noise Actually Feels LikeCharles uses the example of a basket of fries to explain cravings, cues, and automatic eating.[09:55] The Habit Loop: Cue, Routine, RewardCharles revisits the framework from The Power of Habit and applies it directly to food cravings.[10:42] How GLP-1s Interrupt the CueThe fries are still there, but the craving does not activate in the same way.[11:40] What GLP-1s Do in the Body and BrainCharles explains what researchers know about gastric emptying, glucagon-like peptides, and what remains uncertain about the brain.[12:43] What Happens When You StopWhy the medication alone may not be enough if old habits return after discontinuation.[13:36] Pleasure, Food, Alcohol, and AnhedoniaCharles discusses reduced pleasure from food and alcohol, while separating clinical findings from broader claims about losing joy in life.[15:54] Why Charles Stayed With ItEarly changes were not dramatic weight loss, but a growing feeling that eating became more of a choice.[16:40] Eating as a Keystone HabitHow changing food behavior can trigger changes in exercise, alcohol, sleep, focus, and work.[19:31] Why Structure MattersCharles explains why tracking and guided habit systems can help people see patterns they might miss on their own.[20:32] What Changes Physically Over TimeSlower stomach emptying, feeling full longer, more stable blood sugar, and gradual changes in appetite.[21:43] Stated Preferences vs. Revealed PreferencesWhy one part of the brain says “I want to change,” while another part watches what you actually do.[23:22] Identity Change and Habit FormationHow repeated behavior can teach the brain, “I am the kind of person who eats this way” or “I am the kind of person who exercises.”[24:16] Placebo, Belief, and Becoming the Person You Want to BeJames and Charles explore whether placebo effects may work partly by changing identity.[28:07] Alter Egos, Athletes, and RitualsThe conversation turns to Kobe Bryant, Michael Phelps, and how pre-performance routines can cue a desired identity.[29:15] Start With Micro HabitsCharles explains why small behavior changes can compound more effectively than trying to overhaul an entire life at once.[30:40] Charles's First Micro HabitsDrinking less, eating fewer fries, stopping when full, and choosing healthier meals without relying on willpower.[31:24] Feeling Full for the First TimeCharles describes the surprising experience of leaving food unfinished because his body had had enough.[33:03] Why the Stomach ShrinksThe medication does not shrink the stomach directly; eating less over time changes how much food the body expects.[33:21] Why Slower Stomach Emptying HelpsJames asks why a weight-loss drug would slow digestion instead of speeding metabolism.[35:00] The Cumulative EffectWhy the most visible changes often appear after several months, once habits, body size, and identity begin reinforcing each other.[37:03] Is a GLP-1 a Lifelong Drug?Charles explains what research and personal experience suggest about stopping, restarting, and maintaining results.[38:56] James's Health MotivationJames explains that his motivation is not primarily weight loss, but a desire to respond to possible pre-diabetic markers.[39:36] Why Attitude Is Not EnoughCharles argues that wanting to be healthy helps, but habit change still requires structure.[40:02] What Changed at HomeCharles explains how his family's food did not need to change, even though his own choices and portions did.[41:02] Weight, Body Composition, and Pre-DiabetesWhy blood sugar, insulin resistance, fat, and muscle matter more than the scale alone.[42:38] Semaglutide, Tirzepatide, and What Comes NextJames and Charles compare different GLP-1 medications and discuss how newer drugs may work through multiple receptors.[44:27] Will Charles Stop Taking It?Charles explains why he may eventually discontinue the medication, but values having more choice over weight and behavior.[45:24] Blood Work, Snoring, and Health MarkersCharles describes improvements in lab results, cholesterol, snoring, and overall health.[46:31] Who Are We, Really?James and Charles talk about identity, brain chemistry, sugar, alcohol, cravings, and the substances that shape behavior.[48:32] Choosing the Person You Want to BecomeCharles explains how better self-awareness can help people change habits deliberately rather than being pulled by cravings.[49:00] Tracking the ExperimentCharles advises James to track food, feelings, and behavior so he can notice changes that might otherwise be invisible.Additional Resources:Charles Duhigg Official WebsiteThe Power of Habit by Charles DuhiggSupercommunicators by Charles DuhiggNoom's GLP-1 Companion / Habit Formation AnnouncementFDA: Zepbound Approval for Chronic Weight ManagementFDA: Concerns With Unapproved GLP-1 Drugs Used for Weight LossBMJ: Weight Regain After Stopping Weight-Loss MedicationTodd Herman — The Alter Ego EffectSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join primary care professors Mark Ebell, Kate Rowland, Gary Ferenchick and Henry Barry as they discuss 4 new studies: semaglutide for alcohol use disorder, a vibrating cool pack to prevent post vaccination syncope, PCR for 23 respiratory pathogens in primary care to reduce antibiotic use, and fluvoxamine for Long-COVID Fatigue.LinksSemaglutide for AUD: https://pubmed.ncbi.nlm.nih.gov/42070571/Vibrating cool pack for vaccine syncope: https://pubmed.ncbi.nlm.nih.gov/41692229/ Point of care PCR for acute RTI: https://pubmed.ncbi.nlm.nih.gov/42149561/Likelihood that pathogen is commensal vs pathogenic: https://pubmed.ncbi.nlm.nih.gov/39864052/ Fluvoxamine and long COVID: Ann Intern Med. 2026;179(5):621-628  https://pubmed.ncbi.nlm.nih.gov/41911553/

(00:00:00) 224: DOCs Itchy&Bitchy Answer YOUR Questions - Global Edition! (00:00:11) Welcome to Itchy and Bitchy (00:00:42) Doc Itchy Medical Pets Supplements (00:02:32) Hormone Replacement and GLP-1: Navigating Medical Decisions (00:08:06) Brain Fog and Alzheimer's: When to Worry (00:11:11) Menopause in Dogs: A Misunderstanding (00:16:48) The Truth About Alcohol Consumption (00:22:10) GLP-1 and Addiction: A Complex Discussion (00:27:41) Probiotics: The Unknown Frontier (00:32:05) Closing Thoughts on Supplements and Health Ask Docs Itchy&Bitchy:Your Questions on Weight, Hormones, and the GLP-1 additction ...You're writing in from everywhere, and your questions don't hold back, so neither will we. Why is your dog carrying extra weight even though nothing about mealtime has changed? On the human side: does Ozempic actually rewire your brain's reward system, not just your appetite? Emerging research says GLP-1 drugs quiet the same dopamine pathway that drives cravings for food, alcohol, and drugs which raises a wild question we're tackling this season: could a diabetes drug end up treating addiction? We're also digging into whether "Ozempic personality changes" are real, why weight-loss drugs hit women differently at midlife, and what nobody's telling you about pet supplements.Got a question? Send it — nothing's off limits.Visit itchyandbitchy.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/itchy-bitchy-podcast--4303608/support.Itchy & Bitchy: Have you felt dismissed, misdiagnosed, or gaslit by a broken medical system.  From gut health, hormones, autoimmune disease, chronic pain, holistic health, and alternative medicine ... medical gaslighting, patient advocacy , or misdiagnosis we'll call that too.  For chronic illness warriors, self-advocacy seekers: WE OFFER  No BS 

In this episode, I'm joined by board-certified OBGYN and integrative medicine physician Dr. Shawn Tassone to break down one of the fastest-growing topics in health today: peptides. We discuss what peptides are, how they work in the body, and why they've become so popular for everything from weight loss and longevity to muscle recovery and inflammation. We also take a closer look at some of the most talked-about peptides, including semaglutide, tirzepatide, BPC-157, MOTS-c, tesamorelin, and more, discussing the current research, potential benefits, safety concerns, and which ones may actually be worth considering. If you've ever wondered whether peptides are the future of medicine or simply the latest health trend, this episode is for you!

Semaglutide. Tirzepatide. Retatrutide. The peptide conversation has taken over every gym, group chat, and social media feed. But the part about muscle loss, osteopenia, and what the gray market is actually selling you? That part is getting buried. Chalene Johnson sits down with Adam Schafer, co-host of Mind Pump, one of the top fitness podcasts in the world with nearly half a billion downloads. Adam spent three and a half years running real test groups on GLP-1s including Ozempic and Wegovy. What he found changed his perspective entirely and he is not holding back. This conversation covers what is actually driving muscle and bone density loss in women over 40 and 50, why the scale and the mirror are lying about body composition, and what most women are getting wrong about building real strength in midlife. Plus the truth about the gray market and what those peptides may actually contain. This is the conversation the fitness industry is not having and it is one every woman over 40 needs to hear.